WO2018107707A1 - 一种改善心脏病变的方法 - Google Patents
一种改善心脏病变的方法 Download PDFInfo
- Publication number
- WO2018107707A1 WO2018107707A1 PCT/CN2017/089068 CN2017089068W WO2018107707A1 WO 2018107707 A1 WO2018107707 A1 WO 2018107707A1 CN 2017089068 W CN2017089068 W CN 2017089068W WO 2018107707 A1 WO2018107707 A1 WO 2018107707A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- plasminogen
- drugs
- subject
- myocardial
- drug
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
Definitions
- the present invention relates to the treatment of heart disease, especially myocardial damage caused by various causes, cardiac dysfunction.
- Heart disease is a common type of disease, including coronary atherosclerosis, coronary heart disease, angina pectoris, myocardial infarction, arrhythmia, heart failure, pericarditis and so on.
- the factors that cause heart disease are more and affect each other.
- diabetes can cause hyperlipidemia and atherosclerosis due to disorders of fat metabolism, and hyperlipidemia and atherosclerosis in turn aggravate diabetes.
- atherosclerosis is the common pathological basis of many cardiovascular and cerebrovascular diseases, and is the most common disease in cardiovascular diseases, which seriously endangers human health.
- Atherosclerosis includes lipid invasion, platelet activation, thrombosis, intimal damage, inflammatory response, oxidative stress, vascular smooth muscle cell (VSMC) activation, selective matrix metabolism, and vascular remodeling.
- VSMC vascular smooth muscle cell
- vascular remodeling As far as atherosclerosis is concerned, people do not feel any symptoms. The disease is only discovered when the artery connected to an important organ in the body is blocked. Symptoms caused by blocked arteries in the organ are more pronounced. For example, if the heart's blood supply artery is partially blocked, people may feel angina; but if it is completely blocked, it may lead to heart disease (heart tissue death from the blocked arteries).
- AGEs advanced glycation end products
- AGEs can increase neutrophil NADPH oxidase activity and promote vascular oxidative stress by increasing the production of neutrophil oxygen free radicals.
- diabetes since lipid metabolism disorders often occur in combination with diabetes, diabetes is also known as "glycolipidosis.”
- the pathogenesis of diabetes is related to B cell function damage and insulin resistance, which is characterized by chronic hyperglycemia, and the disorder of glucose metabolism often involves disorder of lipid metabolism.
- Diabetic lipid metabolism disorder has become an independent risk factor for cardiovascular disease, mainly characterized by high glycerol Lipemia, low levels of HDL, and increased LDL concentrations. Studies have shown that the incidence and mortality of cardiovascular disease in diabetic patients is significantly higher than non-diabetic patients, diabetes has become an independent risk factor for cardiovascular disease.
- cardiovascular disease has become an independent risk factor for cardiovascular disease [3] , the incidence of atherosclerosis in the cardiovascular disease High, often with diabetes.
- lipid metabolism disorders and diabetic nephropathy.
- Diabetes patients with lipid metabolism disorders elevated lipid deposition in the glomerular basement membrane, stimulate basement membrane cell proliferation and extracellular matrix formation.
- Kimmelstiel and Wilson found large amounts of lipid deposits in the renal arteries, glomeruli, and renal tubules of patients with diabetic nephropathy [7] .
- Abnormal lipid metabolism makes glomerular and tubulointerstitial fibrosis an important cause of progressive damage to renal function [8] .
- the disorder of lipid metabolism itself increases the risk of heart disease in the human body. For example, one of the hazards of fatty liver is to induce or aggravate hypertension, coronary heart disease, and easily lead to myocardial infarction and sudden death.
- the present invention found that plasminogen can specifically treat heart disease and open up new ideas for the treatment of heart disease.
- the invention relates to the following items:
- the invention relates to: 1. A method of preventing or treating myocardial damage in a subject, comprising administering to the subject an effective amount of plasminogen, wherein the subject has a risk of myocardial damage, suspect Have myocardial damage, or suffer from myocardial damage.
- Item 2 The method of Item 1, wherein the myocardial damage comprises ischemia, inflammation, allergy, autoimmunity, thrombosis, microcirculatory disorder, trauma, radiation damage, disorder of glucose metabolism, myocardial damage caused by disorder of fat metabolism.
- the myocardial damage comprises ischemia, inflammation, allergy, autoimmunity, thrombosis, microcirculatory disorder, trauma, radiation damage, disorder of glucose metabolism, myocardial damage caused by disorder of fat metabolism.
- Item 3 The method of Item 1 or 2, wherein the myocardial damage is myocardial damage caused by a disease selected from the group consisting of myocarditis, pericarditis, hypertension, atherosclerosis, coronary heart disease, angina pectoris, myocardial infarction, arrhythmia, heart Decay, shock, diffuse intravascular coagulation, microcirculatory disorders, diabetes, Hyperlipidemia, arterial, venous thrombosis, fat embolism, ischemia-reperfusion, systemic sclerosis, systemic lupus erythematosus, coronary stenosis, rheumatic heart disease, mitral stenosis/hypop of insufficiency, aortic stenosis/ Closed incomplete.
- a disease selected from the group consisting of myocarditis, pericarditis, hypertension, atherosclerosis, coronary heart disease, angina pectoris, myocardial infarction, arrhythmia
- the method of Item 1 or 2, wherein the myocardial damage is myocardial damage caused by an ischemic heart disease.
- ischemic heart disease is atherosclerosis, coronary heart disease, angina pectoris, myocardial infarction, arrhythmia, heart failure, shock, disseminated intravascular coagulation, microcirculatory disorder, ischemia Reperfusion, coronary stenosis, mitral stenosis/hypop of insufficiency, aortic stenosis/insufficiency.
- the method of Item 1 or 2, wherein the myocardial damage is myocardial damage caused by arterial, venous thrombosis or fat embolism.
- Item 7 The method of Item 6, wherein the thrombus or embolism is caused by atherosclerosis.
- the invention in another aspect, relates to: 8.
- a method of preventing or treating myocardial damage in a subject comprising administering to the subject an effective amount of plasminogen to protect myocardial tissue.
- Item 10 The method of Item 8 or 9, wherein the plasminogen promotes repair of damaged myocardium.
- the invention in another aspect, relates to: 14.
- a method of preventing or treating lipid myocardial damage in a subject comprising administering to the subject an effective amount of plasminogen to protect the myocardium.
- the invention relates to: 22.
- a method of preventing or treating inflammatory myocardial damage in a subject comprising administering to the subject an effective amount of plasminogen to protect the myocardium.
- the method of item 23, wherein the inflammation is systemic lupus erythematosus, systemic sclerosis, myocarditis, pericarditis.
- the invention in another aspect, relates to: Item 30.
- a method of preventing or treating coronary atherosclerotic myocardial injury in a subject comprising administering to the subject an effective amount of plasminogen to protect the myocardium.
- the invention in another aspect, relates to: 37.
- a method of preventing or treating diabetes-induced or complicated myocardial injury in a subject comprising administering to the subject an effective amount of plasminogen to protect the myocardium.
- the invention in another aspect, relates to: Item 43.
- a method of preventing or treating myocardial damage caused by lipid deposition in a subject comprising administering to the subject an effective amount of plasminogen.
- lipid deposition is due to hyperlipidemia caused by abnormal fat metabolism or abnormal glucose metabolism in the subject.
- the invention in another aspect, relates to: Item 45.
- a method of preventing or treating renal tissue damage caused by or associated with hyperlipidemia in a subject comprising administering to the subject an effective amount of plasminogen.
- the invention relates to: 46.
- a method of preventing or treating ischemia-reperfusion myocardial tissue damage in a subject comprising administering to the subject an effective amount of plasminogen.
- Item 47 The method of any of claims 1-46, wherein the plasminogen is administered in combination with one or more other drugs or therapeutic means.
- the one or more other drugs include a therapeutic drug for hypertension, a drug for treating diabetes, a drug for treating atherosclerosis, a drug for treating chronic glomerulonephritis, and a treatment for chronic pyelonephritis.
- said other drug comprises: a hypolipidemic drug, an antiplatelet drug, a blood pressure lowering drug, a dilated vascular drug, a hypoglycemic drug, an anticoagulant drug, a thrombolytic drug, a liver protection drug, Antiarrhythmic drugs, cardiotonic drugs, diuretic drugs, anti-infective drugs, antiviral drugs, immunomodulatory drugs, inflammatory regulating drugs, anti-tumor drugs, hormone drugs, thyroxine.
- the drug comprises a hypolipidemic drug: a statin; a fibrate; a niacin; a cholestyramine; clofibrate; an unsaturated fatty acid such as erosin, a blood lipid, and a heart pulse; Sodium alginate; antiplatelet drug: aspirin; dipyridamole; clopidogrel; cilostazol; Dilated vascular drugs: hydralazine; nitroglycerin and Xiaoxintong; sodium nitroprusside; alpha nitrate receptor blockers such as prazosin; alpha receptor blockers such as phentolamine; beta pull receptor stimulants Salbutaline; captopril, enalapril; heart pain, thiazolone; lysine, long-pressure, prostaglandin, atrial natriuretic peptide; thrombolytic drugs: urokinase and streptokin
- any one of claims 1 to 50 wherein the plasminogen has at least 75%, 80%, 85%, 90%, 95%, 96 with the sequence 2, 6, 8, 10 or 12. %, 97%, 98% or 99% sequence identity and still have plasminogen activity.
- Item 52 The method of any one of claims 1 to 51, wherein the plasminogen is added, deleted and/or substituted on the basis of sequence 2, 6, 8, 10 or 12, 1-100, 1-90 , 1-80, 1-70, 1-60, 1-50, 1-45, 1-40, 1-35, 1-30, 1-25, 1-20, 1-15, 1-10, 1 -5, 1-4, 1-3, 1-2, 1 amino acid, and still have plasminogen activity protein.
- Item 53 The method of any of claims 1-52, wherein the plasminogen is a protein comprising a plasminogen active fragment and still having plasminogen activity.
- Item 54 The method of any one of claims 1-53, wherein the plasminogen is selected from the group consisting of Glu-plasminogen, Lys-plasminogen, small plasminogen, microplasminogen, delta- Plasminogen or a variant thereof that retains plasminogen activity.
- Item 55 The method of any of claims 1-54, wherein the plasminogen is a native or synthetic human plasminogen, or a variant or fragment thereof that still retains plasminogen activity.
- Item 61 The method of claim 60, wherein the deficiency or deletion is innate, secondary, and/or local.
- the invention relates to: Item 62.
- the invention relates to: Item 63.
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and plasminogen for use in the method of any of claims 1-61.
- the invention in another aspect, relates to: Item 64.
- a prophylactic or therapeutic kit comprising: (i) plasminogen for use in the method of any of claims 1-61 and (ii) a means for delivering the plasminogen to the subject.
- Item 65 The kit of claim 64, wherein the member is a syringe or vial.
- kit of claim 64 or 65 further comprising a label or instructions for use, the label or instructions for use indicating administration of the plasminogen to the subject to perform any of claims 1-46 The method described in the item.
- the invention in another aspect, relates to: Item 67.
- An article comprising:
- a plasminogen or a plasminogen-containing pharmaceutical composition for use in the method of any of claims 1-61, wherein said label indicates that said plasminogen or composition is administered
- the subject is administered to perform the method of any of claims 1-61.
- Item 68 The kit of any of claims 64-66 or the article of claim 67, further comprising one or more additional members or containers containing other drugs.
- the kit or article of claim 68 wherein the other drug is selected from the group consisting of a hypolipidemic drug, an antiplatelet drug, a blood pressure lowering drug, a dilated vascular drug, a hypoglycemic drug, an anticoagulant drug, a thrombolytic drug. , liver-protecting drugs, anti-arrhythmia drugs, cardiotonic drugs, diuretic drugs, anti-infective drugs, anti-viral drugs, immunomodulatory drugs, inflammatory regulatory drugs, anti-tumor drugs, hormone drugs, thyroxine.
- the invention also relates to the use of plasminogen for the method of any of items 1-61.
- the invention further relates to the use of plasminogen for the preparation of a medicament, a pharmaceutical composition, an article, a kit for use in the method of any of items 1-61.
- the kit or article further comprises an additional one or more components or containers containing other drugs.
- the additional drug is selected from the group consisting of a hypolipidemic drug, an antiplatelet drug, a blood pressure lowering drug, a dilated vascular drug, Hypoglycemic drugs, anticoagulant drugs, thrombolytic drugs, liver protection drugs, antiarrhythmic drugs, cardiotonic drugs, diuretic drugs, anti-infective drugs, antiviral drugs, immunomodulatory drugs, inflammatory regulating drugs, anti-tumor drugs, Hormone drugs, thyroxine.
- the plasminogen is administered systemically or locally, preferably by the following route: intravenous, intramuscular, subcutaneous administration of plasminogen for treatment.
- the plasminogen is administered in combination with a suitable polypeptide carrier or stabilizer.
- the plasminogen is 0.0001-2000 mg/kg, 0.001-800 mg/kg, 0.01-600 mg/kg, 0.1-400 mg/kg, 1-200 mg/kg, 1-100 mg per day.
- the present invention expressly covers all combinations of the technical features between the embodiments of the present invention, and these combined technical solutions are explicitly disclosed in the present application, just as the above technical solutions have been separately and explicitly disclosed.
- the present invention also explicitly covers combinations between various embodiments and elements thereof, and the combined technical solutions are explicitly disclosed herein.
- Plasmin is a key component of the plasminogen activation system (PA system). It is a broad-spectrum protease that hydrolyzes several components of the extracellular matrix (ECM), including fibrin, gelatin, fibronectin, laminin, and proteoglycans. In addition, plasmin activates some metalloproteinase precursors (pro-MMPs) to form active metalloproteinases (MMPs). Therefore, plasmin is considered to be an important upstream regulator of extracellular proteolysis. Plasmin is formed by proteolytic plasminogen by two physiological PAs: tissue plasminogen activator (tPA) or urokinase-type plasminogen activator (uPA).
- tPA tissue plasminogen activator
- uPA urokinase-type plasminogen activator
- PAs Due to the relatively high levels of plasminogen in plasma and other body fluids, it has been traditionally believed that the regulation of the PA system is primarily achieved by the synthesis and activity levels of PAs.
- the synthesis of components of the PA system is tightly regulated by various factors such as hormones, growth factors and cytokines.
- specific physiological inhibitors of plasmin and PAs are also present.
- the main inhibitor of plasmin is ⁇ 2-antiplasmin.
- the activity of PAs is simultaneously inhibited by uPA and tPA plasminogen activator inhibitor-1 (PAI-1) and mainly inhibits uPA lysogen activator inhibitor-2 (PAI-2) adjustment.
- PAI-1 tPA plasminogen activator inhibitor-1
- PAI-2 uPA lysogen activator inhibitor-2
- Some cell surface has a direct hydrolysis activity of uPA-specific cell surface receptor (uPAR).
- Plasminogen is a single-chain glycoprotein consisting of 791 amino acids with a molecular weight of approximately 92 kDa. Plasminogen is mainly synthesized in the liver and is abundantly present in the extracellular fluid. The plasma plasminogen content is approximately 2 ⁇ M. Therefore, plasminogen is a huge potential source of proteolytic activity in tissues and body fluids. Plasminogen exists in two molecular forms: glutamate-plasminogen and Lys-plasminogen. The naturally secreted and uncleaved forms of plasminogen have an amino terminal (N-terminal) glutamate and are therefore referred to as glutamate-plasminogen.
- plasminogen in the presence of plasmin, glutamate-plasminogen is hydrolyzed to Lys-Lysinogen at Lys76-Lys77. Compared to glutamate-plasminogen, lysine-plasminogen has a higher affinity for fibrin and can be activated by PAs at a higher rate.
- the Arg560-Val561 peptide bond of these two forms of plasminogen can be cleaved by uPA or tPA, resulting in the formation of a disulfide-linked double-chain protease plasmin.
- the amino terminal portion of plasminogen contains five homologous tricycles, the so-called kringles, which contain a protease domain.
- Some kringles contain a lysine binding site that mediates the specific interaction of plasminogen with fibrin and its inhibitor alpha2-AP.
- the main substrate for plasmin is fibrin, which is the key to preventing pathological thrombosis.
- Plasmin also has substrate specificity for several components of ECM, including laminin, fibronectin, proteoglycans and gelatin, indicating that plasmin also plays an important role in ECM reconstitution.
- plasmin can also degrade other components of ECM, including MMP-1, MMP-2, MMP-3 and MMP-9, by converting certain protease precursors into active proteases. Therefore, it has been suggested that plasmin may be an important upstream regulator of extracellular proteolysis.
- plasmin has the ability to activate certain potential forms of growth factors. In vitro, plasmin also hydrolyzes components of the complement system and releases chemotactic complement fragments.
- Plasmid is a very important enzyme found in the blood that hydrolyzes fibrin clots into fibrin degradation products and D-dimers.
- Plasmidogen is a zymogen form of plasmin, which is composed of 810 amino acids, based on the sequence in swiss prot, based on the native human plasminogen amino acid sequence (sequence 4) containing the signal peptide. 90kD, a glycoprotein synthesized primarily in the liver and capable of circulating in the blood, encoded The cDNA sequence of this amino acid sequence is shown in SEQ ID NO:3. Full-length plasminogen contains seven domains: a serine protease domain at the C-terminus, a Pan Apple (PAp) domain at the N-terminus, and five Kringle domains (Kringle 1-5).
- PAp Pan Apple
- the signal peptide includes the residue Met1-Gly19
- PAp includes the residue Glu20-Val98
- Kringle1 includes the residue Cys103-Cys181
- Kringle2 includes the residue Glu184-Cys262
- Kringle3 includes the residue Cys275-Cys352
- Kringle4 Including the residue Cys377-Cys454
- Kringle5 includes the residue Cys481-Cys560.
- the serine protease domain includes the residues Val581-Arg804.
- Glu-plasminogen is a natural full-length plasminogen consisting of 791 amino acids (not containing a 19 amino acid signal peptide), and the cDNA sequence encoding the sequence is shown in SEQ ID NO: 1, and its amino acid sequence is sequence 2. Shown. In vivo, there is also a Lys-plasminogen which is hydrolyzed from amino acids 76-77 of Glu-plasminogen, and as shown in SEQ ID NO: 6, the cDNA sequence encoding the amino acid sequence is as shown in SEQ ID NO: 5 Shown. Delta-plasminogen is a fragment of full-length plasminogen deleted from the Kringle2-Kringle5 structure, containing only the Kringle1 and serine protease domains.
- the amino acid sequence of delta-plasminogen has been reported in the literature (sequence 8) A cDNA sequence encoding the amino acid sequence is shown in SEQ ID NO: 7.
- Mini-plasminogen consists of Kringle5 and a serine protease domain, which has been reported in the literature to include the residue Val443-Asn791 (starting amino acid with a Glu residue of Glu-plasminogen sequence not containing a signal peptide)
- the amino acid sequence thereof is shown in SEQ ID NO: 10
- the cDNA sequence encoding the amino acid sequence is shown in SEQ ID NO: 9.
- Micro-plasminogen contains only the serine protease domain, and its amino acid sequence has been reported to include the residue Ala543-Asn791 (from the Glu residue of the Glu-plasminogen sequence containing no signal peptide).
- the amino acid is also reported in the patent document CN102154253A, the sequence of which includes the residue Lys531-Asn791 (the Glu residue of the Glu-plasminogen sequence not containing the signal peptide is the starting amino acid), and the patent sequence refers to the patent document CN102154253A, which The amino acid sequence is shown in SEQ ID NO: 12, and the cDNA sequence encoding the amino acid sequence is shown in SEQ ID NO: 11.
- Plasin of the present invention is used interchangeably with “fibrinolytic enzyme” and “fibrinolytic enzyme”, and has the same meaning; “plasminogen” and “plasminogen”, “fibrinogenase” "Interchangeable use, meaning the same.
- the term "deficiency" of plasminogen means that the content or activity of plasminogen in the subject is lower than that of a normal person, and is low enough to affect the normal physiological function of the subject;
- the meaning of "deficient" of plasminogen is that the content or activity of plasminogen in the subject is significantly lower than that of normal people, and even the activity or expression is minimal, and only by external supply can maintain normal physiological functions.
- plasminogen adopts a closed inactive conformation, but when bound to the surface of a thrombus or cell, it is converted to openness mediated by plasminogen activator (PA).
- PA plasminogen activator
- Conformational active plasmin The active plasmin further hydrolyzes the fibrin clot into a fibrin degradation product and a D-dimer, thereby dissolving the thrombus.
- the PAp domain of plasminogen contains an important determinant that maintains plasminogen in an inactive blocking conformation, while the KR domain is capable of binding to lysine residues present on the receptor and substrate.
- plasminogen activators include tissue plasminogen activator (tPA), urokinase plasminogen activator (uPA), kallikrein, and coagulation factor XII (Hag Mann factor) and so on.
- a "plasminogen active fragment” refers to an active fragment that binds to a target sequence in a substrate and exerts a proteolytic function in a plasminogen protein.
- the technical solution of the present invention relating to plasminogen covers the technical solution of replacing plasminogen with a plasminogen active fragment.
- the plasminogen active fragment of the present invention is a protein comprising a serine protease domain of plasminogen.
- the plasminogen active fragment of the present invention comprises the sequence 14, and the sequence 14 has at least 80%, 90.
- the plasminogen of the present invention comprises a protein comprising the plasminogen active fragment and still retaining the plasminogen activity.
- blood plasminogen and its activity assays include: detection of tissue plasminogen activator activity (t-PAA), detection of plasma tissue plasminogen activator antigen (t-PAAg), Detection of plasma tissue plasminogen activity (plgA), detection of plasma tissue plasminogen antigen (plgAg), detection of plasma tissue plasminogen activator inhibitor activity, inhibition of plasma tissue plasminogen activator Detection of antigens, plasma plasmin-anti-plasmin complex assay (PAP).
- t-PAA tissue plasminogen activator activity
- t-PAAg detection of plasma tissue plasminogen activator antigen
- plgA Detection of plasma tissue plasminogen activity
- plgAg detection of plasma tissue plasminogen antigen
- PAP plasma plasmin-anti-plasmin complex assay
- the most commonly used detection method is the chromogenic substrate method: adding streptokinase (SK) and chromogenic substrate to the plasma to be tested, and the PLG in the tested plasma is converted into PLM under the action of SK, and the latter acts on The chromogenic substrate is then measured spectrophotometrically and the increase in absorbance is directly proportional to the plasminogen activity.
- plasminogen activity in blood can also be measured by immunochemical method, gel electrophoresis, immunoturbidimetry, or radioimmunoassay.
- ortholog or ortholog refers to homologs between different species, including both protein homologs and DNA homologs, also known as orthologs, orthologs. It specifically refers to a protein or gene that has evolved from the same ancestral gene in different species.
- the plasminogen of the present invention includes human natural plasminogen, and also includes plasminogen orthologs or orthologs of plasminogen activity derived from different species.
- Constant substitution variant refers to a change in one of the given amino acid residues without altering the overall conformation and function of the protein or enzyme, including but not limited to similar properties (eg, acidic, basic, hydrophobic, etc.)
- the amino acid replaces the amino acid in the amino acid sequence of the parent protein.
- Amino acids having similar properties are well known. For example, arginine, histidine, and lysine are hydrophilic basic amino acids and are interchangeable.
- isoleucine is a hydrophobic amino acid that can be replaced by leucine, methionine or valine. Therefore, the similarity of two protein or amino acid sequences of similar function may be different.
- Constant substitution variants also includes determining polypeptides or enzymes having more than 60% amino acid identity by BLAST or FASTA algorithm. If it is more than 75%, preferably more than 85%, or even more than 90%. Optimal and have the same or substantially similar properties or functions as the native or parent protein or enzyme.
- Isolated plasminogen refers to a plasminogen protein that is isolated and/or recovered from its natural environment.
- the plasminogen will purify (1) to a purity greater than 90%, greater than 95%, or greater than 98% by weight, as determined by the Lowry method, eg, over 99% (by weight), (2) to a degree sufficient to obtain at least 15 residues of the N-terminal or internal amino acid sequence by using a rotating cup sequence analyzer, or (3) to homogeneity, which is by use Coomassie blue or silver staining was determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing or non-reducing conditions.
- Isolated plasminogen also includes plasminogen prepared from recombinant cells by bioengineering techniques and isolated by at least one purification step.
- polypeptide peptide
- protein protein
- fusion proteins including, but not limited to, fusion proteins having a heterologous amino acid sequence, fusions having heterologous and homologous leader sequences (with or without an N-terminal methionine residue);
- percent amino acid sequence identity with respect to a reference polypeptide sequence is defined as the introduction of a gap as necessary to achieve maximum percent sequence identity, and does not treat any conservative substitution as a sequence.
- Comparisons for the purpose of determining percent amino acid sequence identity can be achieved in a variety of ways within the skill of the art, for example using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art will be able to determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximum contrast over the full length of the sequences being compared. However, for the purposes of the present invention, amino acid sequence identity percent values are generated using the sequence comparison computer program ALIGN-2.
- amino acid sequence identity of a given amino acid sequence A relative to a given amino acid sequence B (or may be expressed as having or comprising relative to, and, or for a given amino acid sequence)
- a given amino acid sequence A of a certain % amino acid sequence identity of B is calculated as follows:
- X is the number of amino acid residues scored by the sequence alignment program ALIGN-2 in the A and B alignments of the program, and wherein Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A relative to B will not be equal to the % amino acid sequence identity of B relative to A. All % amino acid sequence identity values used herein are obtained using the ALIGN-2 computer program as described in the previous paragraph, unless explicitly stated otherwise.
- the terms “treating” and “treating” refer to obtaining a desired pharmacological and/or physiological effect.
- the effect may be to completely or partially prevent the disease or its symptoms, and/or to partially or completely cure the disease and/or its symptoms, and includes: (a) preventing the disease from occurring in the subject, the subject may have The cause of the disease, but not yet diagnosed as having a disease; (b) inhibiting the disease, ie, retarding its formation; and (c) reducing the disease and/or its symptoms, ie causing the disease and/or its symptoms to subside.
- the terms "individual”, “subject” and “patient” are used interchangeably herein to refer to a mammal, including but not limited to a mouse (rat, mouse), a non-human primate, a human, a dog, a cat. Hoofed animals (such as horses, cattle, sheep, pigs, goats).
- “Therapeutically effective amount” or “effective amount” refers to an amount of plasminogen sufficient to effect such prevention and/or treatment of a disease when administered to a mammal or other subject to treat the disease.
- the “therapeutically effective amount” will vary depending on the plasminogen used, the severity of the disease and/or its symptoms of the subject to be treated, and the age, weight, and the like.
- Plasminogen can be isolated and purified from nature for further therapeutic use, or it can be synthesized by standard chemical peptide synthesis techniques. When the polypeptide is chemically synthesized, it can be synthesized in a liquid phase or a solid phase.
- Solid phase polypeptide synthesis SPPS
- Fmoc and Boc Various forms of SPPS, such as Fmoc and Boc, can be used to synthesize plasminogen.
- the attached solid phase free N-terminal amine is coupled to a single N-protected amino acid unit. This unit is then deprotected to reveal a new N-terminal amine that can be attached to other amino acids.
- the peptide remains immobilized on the solid phase and then cut off.
- the plasminogen of the present invention can be produced using standard recombinant methods.
- a nucleic acid encoding plasminogen is inserted into an expression vector operably linked to a regulatory sequence in an expression vector.
- Expression control sequences include, but are not limited to, promoters (eg, naturally associated or heterologous promoters), signal sequences, enhancer elements, and transcription termination sequences.
- Expression regulation can be a eukaryotic promoter system in a vector that is capable of transforming or transfecting eukaryotic host cells (eg, COS or CHO cells). Once the vector is incorporated into a suitable host, the host is maintained under conditions suitable for high level expression of the nucleotide sequence and collection and purification of plasminogen.
- Suitable expression vectors are typically replicated as an episome in the host organism or as an integral part of the host chromosomal DNA.
- expression vectors typically contain a selection marker (eg, ampicillin resistance, hygromycin resistance, tetracycline resistance, kanamycin resistance, or neomycin resistance) to facilitate transformation of the desired DNA sequence with foreign sources. Those cells are tested.
- a selection marker eg, ampicillin resistance, hygromycin resistance, tetracycline resistance, kanamycin resistance, or neomycin resistance
- Escherichia coli is an example of a prokaryotic host cell that can be used to clone a subject antibody-encoding polynucleotide.
- Other microbial hosts suitable for use include bacilli, such as Bacillus subtilis and other enterobacteriaceae, such as Salmonella, Serratia, and various Pseudomonas species. Genus (Pseudomonas) kind.
- expression vectors can also be generated which will typically contain expression control sequences (e.g., origins of replication) that are compatible with the host cell.
- promoters such as the lactose promoter system, the tryptophan (trp) promoter system, the beta-lactamase promoter system, or the promoter system from phage lambda. Promoters typically control expression, optionally in the context of manipulating a gene sequence, and have a ribosome binding site sequence, etc., to initiate and complete transcription and translation.
- yeast can also be used for expression.
- Yeast e.g., S. cerevisiae
- Pichia are examples of suitable yeast host cells in which a suitable vector has expression control sequences (e.g., a promoter), an origin of replication, a termination sequence, and the like, as desired.
- a typical promoter comprises 3-phosphoglycerate kinase and other saccharolytic enzymes.
- Inducible yeast is initiated by a promoter specifically comprising an alcohol dehydrogenase, an isocytochrome C, and an enzyme responsible for the utilization of maltose and galactose.
- mammalian cells e.g., mammalian cells cultured in in vitro cell culture
- an anti-Tau antibody of the invention e.g., a polynucleotide encoding a subject anti-Tau antibody.
- Suitable mammalian host cells include CHO cell lines, various Cos cell lines, HeLa cells, myeloma cell lines, and transformed B cells or hybridomas. Expression vectors for these cells may contain expression control sequences such as origins of replication, promoters and enhancers (Queen et al, Immunol. Rev.
- RNA splice sites sites that are ribosome binding.
- RNA splice sites sites that are ribosome binding.
- polyadenylation sites sites that are ribosome binding sites.
- transcription terminator sequences sites that are ribosome binding sites.
- suitable expression control sequences are promoters derived from the white immunoglobulin gene, SV40, adenovirus, bovine papilloma virus, cytomegalovirus, and the like. See Co et al, J. Immunol. 148: 1149 (1992).
- the invention may be purified according to standard procedures in the art, including ammonium sulfate precipitation, affinity column, column chromatography, high performance liquid chromatography (HPLC), gel electrophoresis, and the like.
- Plasminogen is substantially pure, such as at least about 80% to 85% pure, at least about 85% to 90% pure, at least about 90% to 95% pure, or 98% to 99% pure. Or more pure, for example, free of contaminants, such as cellular debris, macromolecules other than the subject antibody, and the like.
- the jelly can be formed by mixing plasminogen of the desired purity with an optional pharmaceutical carrier, excipient, or stabilizer (Remington's Pharmaceutical Sciences, 16th Edition, Osol, A. ed. (1980)).
- the therapeutic formulation is prepared as a dry formulation or as an aqueous solution.
- Acceptable carriers, excipients, and stabilizers are non-toxic to the recipient at the dosages and concentrations employed, and include buffers such as phosphates, citrates and other organic acids; antioxidants including ascorbic acid and methionine; preservatives such as Octadecyldimethylbenzylammonium chloride; chlorinated hexane diamine; benzalkonium chloride, benzethonium chloride; phenol, butanol or benzyl alcohol; alkyl p-hydroxybenzoic acid Esters such as methyl or propyl p-hydroxybenzoate; catechol; resorcinol; cyclohexanol; 3-pentanol; m-cresol; low molecular weight polypeptide (less than about 10 residues) Protein such as serum albumin, gelatin or immunoglobulin; hydrophilic polymer such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, his
- the formulations of the invention may also contain more than one active compound as required for the particular condition being treated, preferably those having complementary activities and no side effects to each other.
- active compound for example, antihypertensive drugs, antiarrhythmic drugs, drugs for treating diabetes, and the like.
- the plasminogen of the present invention may be encapsulated in microcapsules prepared by, for example, coacervation techniques or interfacial polymerization, for example, may be placed in a glial drug delivery system (eg, liposomes, albumin microspheres, microemulsions, Nanoparticles and nanocapsules are placed in hydroxymethylcellulose or gel-microcapsules and poly-(methyl methacrylate) microcapsules in a macroemulsion.
- glial drug delivery system eg, liposomes, albumin microspheres, microemulsions, Nanoparticles and nanocapsules are placed in hydroxymethylcellulose or gel-microcapsules and poly-(methyl methacrylate) microcapsules in a macroemulsion.
- the plasminogen of the invention for in vivo administration must be sterile. This can be easily achieved by filtration through a sterile filter before or after lyophilization and reconstitution.
- the plasminogen of the present invention can prepare a sustained release preparation.
- sustained release formulations include solid hydrophobic polymeric semi-permeable matrices having a shape and containing glycoproteins, such as films or microcapsules.
- sustained release matrices include polyesters, hydrogels (e.g., poly(2-hydroxyethyl-methacrylate) (Langer et al, J. Biomed. Mater. Res., 15: 167-277 (1981); Langer, Chem .Tech., 12:98-105 (1982)) or poly(vinyl alcohol), polylactide (U.S.
- Patent 3,739,919, EP 58,481 L-glutamic acid and ⁇ -ethyl-L-glutamic acid Copolymer (Sidman, et al, Biopolymers 22: 547 (1983)), not Degraded ethylene-vinyl acetate (Langer, et al., supra), or degradable lactic acid-glycolic acid copolymer such as Lupron DepotTM (from lactic acid-glycolic acid copolymer and leucine hydrazide) Injectable microspheres composed of leuprolide acetate, and poly D-(-)-3-hydroxybutyric acid.
- Lupron DepotTM from lactic acid-glycolic acid copolymer and leucine hydrazide
- Polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid can sustain release molecules for more than 100 days, while some hydrogels release proteins for shorter periods of time.
- a rational strategy for stabilizing proteins can be designed based on relevant mechanisms. For example, if the mechanism of aggregation is found to be an intermolecular SS bond by thiodisulfide bond exchange, it can be modified by modifying the thiol residue, lyophilizing from an acidic solution, controlling humidity, using suitable additives, and developing specific The polymer matrix composition is used to achieve stability.
- compositions of this invention may be effected intramuscularly in different ways, such as by intravenous, intraperitoneal, subcutaneous, intracranial, intrathecal, intraarterial (e.g., via the carotid artery).
- Preparations for parenteral administration include sterile aqueous or nonaqueous solutions, suspensions and emulsions.
- non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
- Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffering media.
- Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, or fixed oils.
- Intravenous vehicles contain liquid and nutritional supplements, electrolyte supplements, and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, antioxidants, chelating agents, and inert gases, and the like.
- the medical staff will determine the dosage regimen based on various clinical factors. As is well known in the medical arts, the dosage of any patient depends on a variety of factors, including the patient's size, body surface area, age, specific compound to be administered, sex, number and route of administration, overall health, and other medications administered simultaneously. .
- the pharmaceutical composition of the present invention comprising plasminogen may be, for example, in the range of about 0.0001 to 2000 mg/kg per day, or about 0.001 to 500 mg/kg (e.g., 0.02 mg/kg, 0.25 mg/kg, 0.5 mg/kg, 0.75 mg/kg, 10 mg/kg, 50 mg/kg, etc.) Subject weight.
- the dose can be 1 mg/kg body weight or 50 mg/kg body weight or in the range of 1-50 mg/kg, or at least 1 mg/kg. Dosages above or below this exemplary range are also contemplated, particularly in view of the above factors. Intermediate doses in the above ranges are also included in the scope of the present invention.
- the subject can administer such doses daily, every other day, every week, or according to any other schedule determined by empirical analysis.
- An exemplary dosage schedule includes 1-10 mg/kg for several days. The therapeutic effect and safety need to be evaluated in real time during the administration of the drug of the present invention.
- One embodiment of the invention relates to an article or kit comprising a plasminogen or plasmin of the invention useful for treating a cardiovascular disease caused by diabetes and a related disorder thereof.
- the article preferably includes a container, label or package insert. Suitable containers are bottles, vials, syringes, and the like.
- the container can be made of various materials such as glass or plastic.
- the container contains a composition that is effective to treat a disease or condition of the invention and has a sterile access port (eg, the container can be an intravenous solution or vial containing a stopper that can be penetrated by a hypodermic needle) of).
- At least one active agent in the composition is plasminogen/plasmin.
- the label on or attached to the container indicates that the composition is used to treat the cardiovascular disease caused by diabetes and its related conditions of the present invention.
- the article of manufacture may further comprise a second container comprising a pharmaceutically acceptable buffer, such as phosphate buffered saline, Ringer's solution, and dextrose solution. It may further comprise other materials required from a commercial and user standpoint, including other buffers, diluents, filters, needles and syringes.
- the article comprises a package insert with instructions for use, including, for example, a user instructing the composition to administer the plasminogen composition and other drugs to treat the accompanying disease.
- Figure 1 Results of serum troponin content after 31 days of administration of plasminogen in 24-25-week-old diabetic mice. The results showed that the concentration of cardiac troponin I in the plasminogen group was significantly lower than that in the vehicle control group, and the statistical difference was extremely significant (** indicates P ⁇ 0.01). This indicates that plasminogen can significantly promote the repair of myocardial injury in mice with diabetes.
- FIG. 2 Statistical results of cardiac organ coefficient after 30 days of plasminogen administration in ApoE atherosclerotic model mice. The results showed that the cardiac organ coefficient of the plasminogen group was significantly lower than that of the vehicle PBS control group. This indicates that plasminogen can ameliorate cardiac compensatory hypertrophy caused by cardiac injury in ApoE atherosclerotic model mice.
- Figure 3 is a representative picture of aortic sinus oil red O staining after 30 days of plasminogen administration in ApoE atherosclerotic model mice.
- A is the vehicle PBS control group and B is the plasminogen group.
- the results showed that the aortic sinus fat deposition (arrow mark) in the plasminogen group was significantly less than that in the vehicle PBS control group. This indicates that plasminogen can improve the deposition of fat in the aortic sinus.
- Figure 4 is a representative picture of aortic valve HE staining after 30 days of plasminogen administration in ApoE atherosclerotic model mice. A and C were given to the vehicle PBS control group, and B and D were given to the plasminogen group. Result It was shown that the aortic valve plaque deposition (arrow mark) in the plasminogen group was significantly less than that in the vehicle PBS control group, and the degree of aortic valve fusion was smaller than the latter. This indicates that plasminogen can improve aortic valve injury in atherosclerotic model mice.
- FIG. 5 is a representative picture of cardiac IgM immunostaining 30 days after administration of plasminogen in ApoE atherosclerotic model mice.
- A is the vehicle PBS control group and B is the plasminogen group.
- the results showed that the positive expression of IgM in the plasminogen group (arrow mark) was significantly less than that in the vehicle PBS control group, indicating that plasminogen can promote the repair of cardiac damage caused by atherosclerosis.
- Figure 6 is a representative picture of aortic sinus Sirius red staining after 30 days of plasminogen administration in ApoE atherosclerotic model mice.
- a and C were given to the vehicle PBS control group, and B and D were given to the plasminogen group.
- the results showed that the area of collagen deposition (arrow mark) in the atherosclerotic vascular wall of the plasminogen group was significantly smaller than that of the vehicle PBS control group, indicating that plasminogen can attenuate the level of aortic sinus fibrosis in atherosclerotic model mice.
- Figure 7 shows the results of a 20-day cardiac risk index calculation of plasminogen in 3% cholesterol hyperlipidemia model mice. The results showed that the CRI of the plasminogen group was significantly smaller than that of the vehicle control group, and the statistical difference was extremely significant. This indicates that plasminogen can effectively reduce the risk of heart disease in mice with hyperlipidemia.
- Figure 8 Results of aortic sinus oil red O staining after administration of plasminogen for 30 days in a 16-week hyperlipidemia model mouse.
- a and C are the control group for the vehicle PBS
- B and D are for the plasminogen group
- E is the quantitative analysis result.
- the results showed that the aortic sinus fat deposition in the plasminogen group was significantly less than that in the vehicle control group, and the statistical difference was significant (* indicates P ⁇ 0.05). This indicates that plasminogen can improve the deposition of fat in the aortic sinus of hyperlipidemia model mice.
- FIG 9 Representative images of HE staining of aortic sinus after 30 days of administration of plasminogen in a 16-week hyperlipidemia model mouse.
- a and C were given to the vehicle PBS control group, and B and D were given to the plasminogen group.
- the results showed that foam cell deposition (marked by the arrow) was observed in the aortic wall of the vehicle control group, and plaque deposition was severe; only mild foam cell deposition was observed in the aortic wall of the plasminogen group, and under the intima No obvious atheroma deposits were found, and the aorta in the plasminogen group was less damaged. This indicates that plasminogen can improve the wall damage caused by lipid deposition in the arterial sinus wall of mice with hyperlipidemia.
- FIG. 10 Immunofibrotic staining of cardiac fibrin after 30 days of administration of plasminogen in a 16-week hyperlipidemia model mouse.
- A is the control vehicle PBS control group
- B is the plasminogen group
- C is the quantitative analysis result.
- the results showed that the positive expression of cardiac fibrin in the plasminogen group was significantly less than that.
- the vehicle was administered to the PBS control group, and the statistical difference was significant (* indicates P ⁇ 0.05). This indicates that plasminogen can reduce heart damage caused by hyperlipidemia.
- FIG 11 Representative images of cardiac IgM immunostaining 30 days after administration of plasminogen in a 16-week hyperlipidemia model mouse.
- A is the vehicle PBS control group and B is the plasminogen group.
- the results showed that the positive expression of IgM in the plasminogen group was significantly less than that in the vehicle PBS control group, indicating that plasminogen can alleviate the heart damage caused by hyperlipidemia.
- Figure 12 Representative pictures of Sirius red staining after 30 days of plasminogen administration in a 16-week hyperlipidemia model mouse.
- A is the vehicle PBS control group and B is the plasminogen group.
- the results showed that the deposition of collagen in the plasminogen group was significantly less than that in the vehicle PBS control group, indicating that plasminogen can alleviate cardiac fibrosis in hyperlipidemia model mice.
- FIG. 13 Serum troponin assay results after administration of plasminogen for 30 days in a 16-week hyperlipidemia model mouse. The results showed that the concentration of serum cardiac troponin in the control group was significantly higher than that in the plasminogen group, and the statistical difference was significant (* indicates P ⁇ 0.05). This indicates that plasminogen can repair the damage of hyperlipidemic heart.
- FIG 14 Representative pictures of ventricular oil red O staining after 26 days of administration of plasminogen in 26-week-old diabetic mice.
- A is the vehicle PBS control group and B is the plasminogen group.
- the results showed that ventricular lipid deposition (arrow markers) was significantly less in the plasminogen group than in the vehicle PBS control group. This indicates that plasminogen can reduce ventricular lipid deposition in diabetic mice and promote the repair of ventricular injury.
- Figure 15 Representative images of aortic sinus simulone red staining after administration of plasminogen for 16 weeks in a 16-week-old hyperlipidemia model mouse.
- a and C were given to the vehicle PBS control group, and B and D were given to the plasminogen group.
- the results showed that the area of collagen deposition (arrow mark) in the vascular sinus of the plasminogen group was significantly smaller than that of the vehicle PBS control group, indicating that plasminogen can attenuate the aortic sinus fibrosis in hyperlipidemia model mice. Level.
- Figure 16 is a representative picture of Sirius red staining after zebramycin-induced systemic sclerosis in mice 21 days after administration of plasminogen.
- A is the vehicle PBS control group and B is the plasminogen group.
- B is the plasminogen group.
- the study found that in the bleomycin-induced systemic sclerosis mouse model, the concentration of collagen deposition (arrow mark) in the vehicle control group was higher than that in the plasminogen group. This indicates that plasminogen can effectively reduce bleomycin-induced cardiac fibrosis.
- Figure 17 Results of cardiac masson staining after 31 days of administration of plasminogen in 24-25-week-old diabetic mice.
- A is the vehicle PBS control group and B is the plasminogen group.
- the results showed that blue hyperplastic collagen fibers (arrow marks) were observed between the myocardial fibers of the vehicle control PBS control group. Mild myocardial fibrosis; a small amount of light blue hyperplastic collagen fibers were seen between the myocardial fibers in the plasminogen group, and myocardial fibrosis was significantly reduced compared with the control group. This indicates that plasminogen can improve the fibrosis of the heart of diabetic mice.
- FIG 18 Representative pictures of Sirius red staining after 17 days of administration of plasminogen in 17-18 week old diabetic mice.
- A is the vehicle PBS control group and B is the plasminogen group.
- the results showed that the deposition of collagen fibers (arrow marks) in the plasminogen group was significantly less than that in the vehicle PBS control group. This indicates that plasminogen can reduce fibrosis in the heart of diabetic mice.
- FIG 19 Representative pictures of Sirius red staining after 26 days of administration of plasminogen in 26-27 week old diabetic mice.
- A is the vehicle PBS control group and B is the plasminogen group.
- the results showed that the deposition of collagen (arrow mark) in the plasminogen group was significantly less than that in the vehicle PBS control group. This indicates that plasminogen can attenuate the fibrosis of the heart of diabetic mice.
- Figure 20 shows the results of ventricular oil red O staining of mice with plasminogen 30-day ApoE atherosclerosis model.
- A is the control vehicle PBS control group
- B is the plasminogen group
- C is the quantitative analysis result.
- the results showed that the ventricular lipid deposition (arrow mark) in the plasminogen group was significantly less than that in the vehicle PBS control group, and the statistical difference was significant (* indicates P ⁇ 0.05). This indicates that plasminogen can reduce ventricular lipid deposition in atherosclerotic model mice and promote the repair of ventricular damage caused by lipid deposition.
- Figure 21 is a representative picture of Sirius red staining after 30 days of plasminogen administration in ApoE atherosclerotic model mice.
- A is the vehicle PBS control group and B is the plasminogen group.
- the results showed that the deposition of collagen in the plasminogen group (arrow mark) was significantly less than that in the vehicle PBS control group, indicating that plasminogen can attenuate cardiac fibrosis in ApoE atherosclerotic model mice.
- Cardiovascular atherosclerosis can lead to ischemic damage to cardiomyocytes.
- Cardiac troponin I (CTNI) is an important marker of myocardial injury, and its serum concentration can reflect the degree of myocardial damage [3] .
- CNI Cardiac troponin I
- mice Twenty-eight male db/db mice aged 24-25 weeks were randomly divided into two groups, 12 in the vehicle PBS control group and 16 in the plasminogen group. On the day of the start of the experiment, the day 0 was recorded and the group was weighed. The day after the grouping, plasminogen or PBS was given and recorded as the first day, and the drug was administered continuously for 31 days. Plasmin The original group of mice was injected with plasminogen at a dose of 2 mg/0.2 ml/day/day, and the same volume of PBS was administered to the vehicle PBS control group by tail vein injection.
- mice at 6 weeks of age were fed a high-fat, high-cholesterol diet (Nantong Trofe, TP2031) for 16 weeks to induce an atherosclerosis model [4,5] .
- the mice after the modeling were taken 50 ⁇ l of blood for three days before the administration to detect the total cholesterol (T-CHO) content, and were randomly divided into two groups according to the T-CHO content, and the vehicle PBS control group was given 7 cells. 6 lysogen group.
- the first dose was started on the first day.
- the plasminogen group was injected with human plasminogen 1 mg/0.1 mL/day/day into the tail vein, and the same volume of PBS was injected into the tail of the vehicle PBS control group.
- Cardiac coefficient (%) heart weight / body weight ⁇ 100.
- mice at 6 weeks of age were fed a high-fat, high-cholesterol diet (Nantong Trofe, TP2031) for 16 weeks to induce an atherosclerosis model [4,5] .
- the mice after the modeling were taken 50 ⁇ l of blood for three days before the administration to detect the total cholesterol (T-CHO) content, and were randomly divided into two groups according to the T-CHO content, and the vehicle PBS control group was given 7 cells. 6 lysogen group.
- the first dose was started on the first day.
- the plasminogen group was injected with human plasminogen 1 mg/0.1 mL/day/day into the tail vein, and the same volume of PBS was injected into the tail of the vehicle PBS control group.
- mice were sacrificed for 30 days, and the mice were sacrificed on the 31st day.
- the hearts were fixed in 4% paraformaldehyde for 24-48 hours, respectively, in a 15%, 30% sucrose solution at 4 ° C overnight, embedded in OCT, and frozen section thickness. 8 ⁇ m, oil red O staining for 15min, 75% alcohol differentiation for 5 seconds, hematoxylin staining for 30 seconds, glycerin gelatin seal. Sections were observed under a 200x optical microscope.
- aortic sinus fat deposition (arrow mark) was significantly less in the plasminogen group (Fig. 3B) than in the vehicle PBS control group (Fig. 3A). This indicates that plasminogen can improve aortic sinus fat deposition in atherosclerosis.
- mice at 6 weeks of age were fed a high-fat, high-cholesterol diet (Nantong Trofe, TP2031) for 16 weeks to induce an atherosclerosis model [4,5] .
- the mice after the modeling were taken 50 ⁇ l of blood for three days before the administration to detect the total cholesterol (T-CHO) content, and were randomly divided into two groups according to the T-CHO content, and the vehicle PBS control group was given 7 cells. 6 lysogen group.
- the first dose was started on the first day.
- the plasminogen group was injected with human plasminogen 1 mg/0.1 ml/day/day into the tail vein, and the same volume of PBS was injected into the tail of the vehicle PBS control group.
- the high fat and high cholesterol feed was continued to be fed during the administration.
- Mice were sacrificed on day 31 and hearts were fixed in 4% paraformaldehyde for 24-48 hours.
- the fixed tissue samples were dehydrated by alcohol gradient and transparent to xylene for paraffin embedding.
- the thickness of the aortic sinus tissue section was 3 ⁇ m.
- the sections were dewaxed and rehydrated and stained with hematoxylin and eosin (HE staining). After 1% hydrochloric acid alcohol differentiation, the ammonia water returned to the blue and dehydrated with an alcohol gradient.
- the sections were 40 times (Fig. 4A). And 4B) and 200 times (Fig. 4C and 4D) were observed under an optical microscope.
- the staining results showed that the lipid plaque deposition (arrow mark) of the aortic sinus in the plasminogen group (Fig. 4B, 4D) was significantly less than that in the vehicle PBS control group (Fig. 4A, 4C), and aortic valve fusion. The former is smaller than the latter. This indicates that plasminogen can improve aortic valve injury in atherosclerosis.
- mice at 6 weeks of age were fed a high-fat, high-cholesterol diet (Nantong Trofe, TP2031) for 16 weeks to induce an atherosclerosis model [4,5] .
- the mice after the modeling were taken 50 ⁇ l of blood for three days before the administration to detect the total cholesterol (T-CHO) content, and were randomly divided into two groups according to the T-CHO content, and the vehicle PBS control group was given 7 cells. 6 lysogen group.
- the first dose was started on the first day.
- the plasminogen group was injected with human plasminogen 1 mg/0.1 ml/day/day into the tail vein, and the same volume of PBS was injected into the tail of the vehicle PBS control group.
- the high fat and high cholesterol feed was continued to be fed during the administration.
- Mice were sacrificed on day 31 and hearts were fixed in 4% paraformaldehyde for 24-48 hours.
- the fixed tissue was paraffin-embedded after dehydration by alcohol gradient and transparency of xylene.
- the thickness of the tissue section was 3 ⁇ m, and the sections were dewaxed and rehydrated and washed once with water.
- the PAP pen looped out of the tissue, incubated with 3% hydrogen peroxide for 15 minutes, and washed twice with 0.01 M PBS for 5 minutes each time.
- IgM antibodies play an important role in the clearance of apoptotic and necrotic cells.
- the level of local IgM antibodies in tissue and organ damage is positively correlated with the degree of injury [6,7] . Therefore, detecting the level of local IgM antibodies in tissues and organs can reflect the damage of the tissues and organs. It was found that the positive expression of cardiac IgM in the plasminogen group (Fig. 5B) was significantly less than that in the vehicle PBS control group (Fig. 5A). This indicates that plasminogen can significantly improve myocardial damage in ApoE mice.
- mice at 6 weeks of age were fed a high-fat, high-cholesterol diet (Nantong Trofe, TP2031) for 16 weeks to induce an atherosclerosis model [4,5] .
- the mice after the modeling were taken 50 ⁇ l of blood for three days before the administration to detect the total cholesterol (T-CHO) content, and were randomly divided into two groups according to the T-CHO content, and the vehicle PBS control group was given 7 cells. 6 lysogen group.
- the first dose was started on the first day.
- the plasminogen group was injected with human plasminogen 1 mg/0.1 ml/day/day into the tail vein, and the same volume of PBS was injected into the tail of the vehicle PBS control group.
- the high fat and high cholesterol feed was continued to be fed during the administration.
- Mice were sacrificed on day 31 and hearts were fixed in 4% paraformaldehyde for 24-48 hours.
- the fixed tissue was paraffin-embedded after dehydration by alcohol gradient and transparency of xylene.
- the thickness of the tissue section was 3 ⁇ m.
- the sections were dewaxed and rehydrated, washed once with water, stained with 0.1% Sirius red saturated picric acid for 30 minutes, rinsed with running water for 2 min, stained with hematoxylin for 1 minute, rinsed with water, differentiated with 1% hydrochloric acid, and returned to blue with ammonia. Rinse with running water, dry and seal with neutral gum, and observe under a 200x optical microscope.
- Sirius red staining can permanently stain collagen, which is a special staining method for collagen tissue in pathological sections to specifically display collagen tissue.
- mice Sixteen-week-old male C57 mice were fed with 3% cholesterol and high-fat diet (Nantong Trofe) for 4 weeks to induce hyperlipidemia [8,9] .
- This model was designated as a model of 3% cholesterol hyperlipidemia.
- the modeled mice continued to be fed a 3% cholesterol high fat diet.
- 50 ⁇ l of blood was taken from each mouse three days before administration, and total cholesterol (T-CHO) was measured, and randomly divided into two groups according to the total cholesterol concentration, 8 in each group. The start of administration was recorded as the first day, and the plasminogen group mice were injected with human plasminogen 1 mg/0.1 ml/day/day into the tail vein, and the same volume of PBS was injected into the tail of the vehicle PBS control group.
- mice After the 20th day of administration, the mice began to fast, fasted for 16 hours, and on the 21st day, 50 ⁇ L of blood was taken from the iliac venous plexus, and the supernatant was obtained by centrifugation.
- the total cholesterol content was determined by the total cholesterol test kit (Nanjing Jianshe Bioengineering Research Institute). , Item No. A111-1) was tested; high-density lipoprotein cholesterol (HDL-C) content was detected using a high-density lipoprotein cholesterol test kit (Nanjing Institute of Bioengineering, item number A112-1).
- Cardiac risk index is used to assess the risk of dyslipidemia-induced heart disease [10] .
- Cardiac risk index T-CHO/HDL-C.
- Example 8 Plasminogen-reducing lipid deposition in aortic sinus of a 16-week hyperlipidemia model mouse
- mice Nine-year-old male C57 mice were fed a high-fat, high-cholesterol diet (Nantong Trophy, TP2031) for 16 weeks to induce a hyperlipidemia model [8,9]] . This model was designated as 16-week hyperlipemia.
- the start of administration was recorded as the first day, and the plasminogen group was injected with human plasminogen 1 mg/0.1 ml/day/day into the tail vein, and the same volume of PBS was injected into the tail of the vehicle PBS control group.
- the mice were sacrificed for 30 days, and the mice were sacrificed on the 31st day.
- the heart tissue was fixed in 4% paraformaldehyde for 24-48 hours, respectively, in a 15%, 30% sucrose overnight at 4 ° C, OCT embedding, aorta
- the sinus frozen section thickness was 8 ⁇ m, oil red O staining for 15 min, 75% alcohol differentiation for 5 seconds, hematoxylin staining for 30 s, and glycerin gelatin for sealing.
- the sections were observed under 40 (Fig. 8A, 8B), 200 times (Fig. 8C, 8D) magnification optical microscope.
- mice 11-year-old male C57 mice were fed a high-fat, high-cholesterol diet (Nantong Trophy, item number TP2031) for 16 weeks to induce a hyperlipidemia model [8,9] , which was defined as 16-week hyperlipidemia.
- TP2031 high-fat, high-cholesterol diet
- Mice after modeling continue to feed high cholesterol feed. 50 ⁇ l of blood was taken from each of the three days before administration to detect the total cholesterol (T-CHO) content, and was randomly divided into two groups according to the T-CHO content, 6 in the vehicle PBS control group, and 5 in the plasminogen group. .
- the start of administration was recorded as the first day, and the plasminogen group was injected with human plasminogen 1 mg/0.1 ml/day/day into the tail vein, and the same volume of PBS was injected into the tail of the vehicle PBS control group.
- the mice were administered for 30 days, and the mice were sacrificed on the 31st day, and the heart tissue was fixed in 4% paraformaldehyde for 24-48 hours.
- the fixed tissue was paraffin-embedded after dehydration by alcohol gradient and transparency of xylene.
- the fixed tissue samples were dehydrated by alcohol gradient and transparent to xylene for paraffin embedding.
- the thickness of the aortic sinus tissue section was 3 ⁇ m.
- the sections were dewaxed and rehydrated and stained with hematoxylin and eosin (HE staining). After 1% hydrochloric acid alcohol was differentiated, the ammonia water returned to blue and dehydrated with an alcohol gradient. The slices were cut at 40 (Fig. 9A, B). 200 times (Fig. 9C, D) observed under an optical microscope.
- Example 10 Plasminogen reduces the expression of cardiac fibrin in a mouse model of hyperlipidemia at 16 weeks
- mice 11-year-old male C57 mice were fed a high-fat, high-cholesterol diet (Nantong Trophy, item number TP2031) for 16 weeks to induce a hyperlipidemia model [8,9] , which was defined as 16-week hyperlipidemia.
- TP2031 high-fat, high-cholesterol diet
- Mice after modeling continue to feed high cholesterol feed. 50 ⁇ l of blood was taken from each of the three days before administration to detect the total cholesterol (T-CHO) content, and was randomly divided into two groups according to the T-CHO content, 6 in the vehicle PBS control group, and 5 in the plasminogen group. .
- the start of administration was recorded as the first day, and the plasminogen group was injected with human plasminogen 1 mg/0.1 ml/day/day into the tail vein, and the same volume of PBS was injected into the tail of the vehicle PBS control group.
- the mice were administered for 30 days, and the mice were sacrificed on the 31st day, and the heart tissue was fixed in 4% paraformaldehyde for 24-48 hours.
- the fixed tissue was paraffin-embedded after dehydration by alcohol gradient and transparency of xylene.
- the thickness of the tissue section was 3 ⁇ m, and the sections were dewaxed and rehydrated and washed once with water. Incubate for 15 minutes with 3% hydrogen peroxide and wash twice with water for 5 minutes each time.
- the color was developed according to the DAB kit (Vector Laboratories, Inc., USA), washed three times with water, and counterstained with hematoxylin for 30 seconds, and rinsed with running water for 5 minutes.
- the gradient alcohol was dehydrated, the xylene was transparent and the neutral gum was sealed, and the sections were observed under a 200-fold optical microscope.
- Fibrinogen is a precursor of fibrin.
- fibrinogen is hydrolyzed into fibrin deposits at the site of injury [11,12] . Therefore, the level of damaged local fibrin can be used as a marker of the degree of damage.
- Example 11 Plasminogen effectively protects myocardial injury in a 16-week hyperlipidemia model mouse
- mice 11-year-old male C57 mice were fed a high-fat, high-cholesterol diet (Nantong Trophy, item number TP2031) for 16 weeks to induce a hyperlipidemia model [8,9] , which was defined as 16-week hyperlipidemia.
- TP2031 high-fat, high-cholesterol diet
- Mice after modeling continue to feed high cholesterol feed. 50 ⁇ l of blood was taken from each of the three days before administration to detect the total cholesterol (T-CHO) content, and was randomly divided into two groups according to the T-CHO content, 6 in the vehicle PBS control group, and 5 in the plasminogen group. .
- the start of administration was recorded as the first day, and the plasminogen group was injected with human plasminogen 1 mg/0.1 ml/day/day into the tail vein, and the same volume of PBS was injected into the tail of the vehicle PBS control group.
- the mice were administered for 30 days, and the mice were sacrificed on the 31st day, and the heart tissue was fixed in 4% paraformaldehyde for 24-48 hours.
- the fixed tissue was paraffin-embedded after dehydration by alcohol gradient and transparency of xylene.
- the thickness of the tissue section was 3 ⁇ m, and the sections were dewaxed and rehydrated and washed once with water. Incubate for 15 minutes with 3% hydrogen peroxide and wash twice with water for 5 minutes each time.
- IgM antibodies play an important role in the clearance of apoptotic and necrotic cells, and the level of local IgM antibodies in damaged tissues is positively correlated with the degree of injury [6,7] . Therefore, detecting the level of local IgM antibodies in tissues and organs can reflect the degree of damage of the tissues and organs.
- Example 12 Plasminogen attenuates cardiac fibrosis in a 16-week hyperlipidemia model mouse
- mice 11-year-old male C57 mice were fed a high-fat, high-cholesterol diet (Nantong Trophy, item number TP2031) for 16 weeks to induce a hyperlipidemia model [8,9] , which was defined as 16-week hyperlipidemia.
- TP2031 high-fat, high-cholesterol diet
- Mice after modeling continue to feed high cholesterol feed. 50 ⁇ l of blood was taken from each of the three days before administration to detect the total cholesterol (T-CHO) content, and was randomly divided into two groups according to the T-CHO content, 6 in the vehicle PBS control group, and 5 in the plasminogen group. .
- the start of administration was recorded as the first day, and the plasminogen group was injected with human plasminogen 1 mg/0.1 ml/day/day into the tail vein, and the same volume of PBS was injected into the tail of the vehicle PBS control group.
- the mice were administered for 30 days, and the mice were sacrificed on the 31st day, and the heart tissue was fixed in 4% paraformaldehyde for 24-48 hours.
- the fixed tissue was paraffin-embedded after dehydration by alcohol gradient and transparency of xylene. The thickness of the tissue section was 3 ⁇ m.
- the sections were dewaxed and rehydrated, washed once with water, stained with 0.1% Sirius red saturated picric acid for 30 minutes, rinsed with running water for 2 min, stained with hematoxylin for 1 minute, rinsed with water, differentiated with 1% hydrochloric acid, and returned to blue with ammonia. Rinse with running water, dry and seal with neutral gum, and observe under a 200x optical microscope.
- Sirius red staining can make collagen staining for a long time. As a special staining method for pathological sections, Sirius red staining can specifically display collagen tissue.
- Example 13 plasminogen repair 16-week hyperlipidemia model mice myocardial injury
- mice 11-year-old male C57 mice were fed a high-fat, high-cholesterol diet (Nantong Trophy, item number TP2031) for 16 weeks to induce a hyperlipidemia model [8,9] , which was defined as 16-week hyperlipidemia.
- TP2031 high-fat, high-cholesterol diet
- Mice after modeling continue to feed high cholesterol feed. 50 ⁇ l of blood was taken from each of the three days before administration to detect the total cholesterol (T-CHO) content, and was randomly divided into two groups according to the T-CHO content, 6 in the vehicle PBS control group, and 5 in the plasminogen group. .
- the start of administration was recorded as the first day, and the plasminogen group was injected with human plasminogen 1 mg/0.1 ml/day/day into the tail vein, and the same volume of PBS was injected into the tail of the vehicle PBS control group.
- the mice began to fast after the 30th day of administration, fasting for 16 hours.
- the eyeballs were taken for blood collection, and the supernatant was obtained by centrifugation.
- Cardiac troponin I (CTNI) detection kit was used. (Nanjing built) to measure the concentration of troponin in serum.
- Cardiac troponin I is an important marker of myocardial injury, and its serum concentration can reflect the degree of myocardial damage [3] .
- mice at 26 weeks of age were randomly assigned to 4 rats in the plasminogen group and 5 to the vehicle PBS control group.
- the plasminogen group was injected with human plasminogen 2 mg/0.2 ml/day/day into the tail vein, and the same volume of PBS was injected into the tail of the vehicle PBS control group for 35 days.
- the mice were sacrificed on the 36th day, and the hearts were fixed in 4% paraformaldehyde for 24-48 hours, respectively, in 15%, 30% sucrose at 4 ° C overnight, embedded in OCT, frozen section thickness 8 ⁇ m, oil red O staining 15 min, 75% alcohol differentiation for 5 seconds, hematoxylin staining for 30s, glycerin gelatin seal. Sections were observed under a 200x optical microscope.
- ventricular lipid deposition (arrow mark) was significantly less in the plasminogen group (Fig. 14B) than in the vehicle PBS control group (Fig. 14A). This indicates that plasminogen can reduce the deposition of fat in the ventricle of diabetic mice and promote the repair of ventricular damage.
- mice 11-year-old male C57 mice were fed a high-fat, high-cholesterol diet (Nantong Trophy, item number TP2031) for 16 weeks to induce a hyperlipidemia model [8,9] , which was defined as 16-week hyperlipidemia.
- TP2031 high-fat, high-cholesterol diet
- Mice after modeling continue to feed high cholesterol feed. 50 ⁇ l of blood was taken from each of the three days before administration to detect the total cholesterol (T-CHO) content, and was randomly divided into two groups according to the T-CHO content, 6 in the vehicle PBS control group, and 5 in the plasminogen group. .
- the start of administration was recorded as the first day, and the plasminogen group was injected with human plasminogen 1 mg/0.1 ml/day/day into the tail vein, and the same volume of PBS was injected into the tail of the vehicle PBS control group.
- the mice were sacrificed on the 31st day, and the hearts were fixed in 4% paraformaldehyde for 24-48 hours.
- the fixed tissue was paraffin-embedded after dehydration by alcohol gradient and transparency of xylene.
- the thickness of the aortic sinus slice was 3 ⁇ m. The slice was dewaxed and rehydrated and washed once.
- Ten 12-week-old C57 male rats were randomly divided into two groups, one for the vehicle PBS control group and five for the plasminogen group. On the day of the start of the experiment, the day 0 was recorded and the group was weighed. On the first day, the model was administered. The subcutaneous injection of bleomycin at 0.1 mg/0.1 ml/day/day induced systemic sclerosis [13] and began to give Plasminogen or PBS was administered continuously for 21 days. The plasminogen group was injected with plasminogen at a dose of 1 mg/0.1 ml/day/day, and the same volume of PBS was injected into the tail of the vehicle PBS control group.
- mice were sacrificed on the 22nd day and the heart was taken at 4 Fix in % paraformaldehyde fixative for 24 hours.
- the fixed heart was dehydrated by alcohol gradient and transparent to xylene for paraffin embedding.
- the thickness of the tissue section was 3 ⁇ m.
- the sections were dewaxed to water and washed once with water. After staining with 0.1% Sirius red saturated picric acid for 30 minutes, rinsed with running water for 2 min, hematoxylin staining for 1 minute, running water rinse, 1% hydrochloric acid alcohol differentiation, ammonia water returning to blue Rinse with running water, dry and seal with neutral gum, and observe under a 200x optical microscope.
- mice Ten male db/db rats aged 24-25 weeks were randomly divided into two groups, the vehicle PBS control group and the plasminogen group, with 5 rats in each group. On the day of the start of the experiment, the day 0 was recorded and the group was weighed, and on the first day, plasminogen or PBS was administered for 31 days. The plasminogen group was injected with plasminogen at 2 mg/0.2 ml/day/day in the tail vein, and the same volume of PBS was administered to the vehicle PBS control group. Mice were sacrificed 31 days after plasminogen and cardiac tissue was fixed in 4% paraformaldehyde fixative for 24 hours. The fixed heart tissue was dehydrated by alcohol gradient and transparent to xylene for paraffin embedding.
- the tissue section was 4 ⁇ m thick, and the sections were dewaxed and rehydrated, and then placed in a potassium dichromate solution overnight. Iron hematoxylin is dyed for 3 to 5 minutes, and the water is slightly washed. 1% hydrochloric acid alcohol was differentiated, treated with ammonia for 1 second, and washed with water. Lichun red acid magenta solution is dyed for 8 minutes and rinsed quickly in water. The aqueous solution of 1% phosphomolybdic acid was treated for about 2 minutes, and the aniline blue solution was counterstained for 6 minutes. 1% glacial acetic acid rinse for about 1 minute. The dried ethanol was dehydrated and the xylene was transparently sealed, and the sections were observed under a 200-fold optical microscope.
- the most common complication of diabetes is excessive accumulation of connective tissue (pathological fibrosis), which may be a characteristic pathological change in diabetic cardiomyopathy [14,15] .
- Masson staining can show fibrosis of the tissue.
- the results showed that blue hyperplastic collagen fibers (arrow marks) were observed between the myocardial fibers in the vehicle PBS control group (Fig. 17A), showing mild myocardial fibrosis; in the plasminogen group (Fig. 17B) A small amount of light blue can be seen Compared with the control group, myocardial fibrosis was significantly reduced in the color-proliferating collagen fibers. This indicates that plasminogen can improve the fibrosis of the heart of diabetic mice.
- the thickness of the tissue section was 3 ⁇ m.
- the sections were dewaxed to water and washed once with water. After staining with 0.1% Sirius red saturated picric acid for 30 minutes, rinsed with running water for 2 min, hematoxylin staining for 1 minute, running water rinse, 1% hydrochloric acid alcohol differentiation, ammonia water returning to blue Rinse with running water, dry and seal with neutral gum, and observe under a 200x optical microscope.
- mice Nine male db/db males from 26 to 27 weeks old were randomly divided into two groups, 5 in the vehicle control group and 4 in the plasminogen group. On the day of the start of the experiment, the day 0 was recorded and the group was weighed, and on the first day, plasminogen or PBS was administered for 35 days. The plasminogen group was injected with plasminogen at 2 mg/0.2 ml/day/day in the tail vein, and the same volume of PBS was administered to the vehicle PBS control group. Mice were sacrificed 35 days after plasminogen and cardiac tissue was fixed in 4% paraformaldehyde fixative for 24 hours. The fixed heart was dehydrated by alcohol gradient and transparent to xylene for paraffin embedding.
- the thickness of the tissue section was 3 ⁇ m.
- the sections were dewaxed to water, washed once with water, stained with 0.1% Sirius red for 60 minutes, rinsed with running water, stained with hematoxylin for 1 minute, rinsed with running water, 1% hydrochloric acid and ammonia were rehydrated to blue, rinsed with water. After drying, the sheets were mounted and observed under a 200x optical microscope.
- mice at 6 weeks of age were fed a high-fat, high-cholesterol diet (Nantong Trofe, TP2031) for 16 weeks to induce an atherosclerosis model [4,5] .
- the mice after the modeling were taken 50 ⁇ l of blood for three days before the administration to detect the total cholesterol (T-CHO) content, and were randomly divided into two groups according to the T-CHO content, and the vehicle PBS control group was given 7 cells. 6 lysogen group.
- the first dose was started on the first day.
- the plasminogen group was injected with human plasminogen 1 mg/0.1 mL/day/day into the tail vein, and the same volume of PBS was injected into the tail of the vehicle PBS control group.
- mice were sacrificed for 30 days, and the mice were sacrificed on the 31st day.
- the hearts were fixed in 4% paraformaldehyde for 24-48 hours, respectively, in a 15%, 30% sucrose solution at 4 ° C overnight, OCT was embedded, and ventricular frozen sections were taken.
- the thickness was 8 ⁇ m, oil red O staining for 15 min, 75% alcohol differentiation for 5 seconds, hematoxylin staining for 30 seconds, and glycerin gelatin for sealing. Sections were observed under a 200x optical microscope.
- ventricular lipid deposition (arrow mark) was significantly less in the plasminogen group (Fig. 20B) than in the vehicle PBS control group (Fig. 20A), and the statistical difference was significant (Fig. 20C). This indicates that plasminogen can reduce ventricular lipid deposition in atherosclerotic model mice and promote the repair of ventricular damage caused by lipid deposition.
- mice at 6 weeks of age were fed a high-fat, high-cholesterol diet (Nantong Trofe, TP2031) for 16 weeks to induce an atherosclerosis model [4,5] .
- the mice after the modeling were taken 50 ⁇ l of blood for three days before the administration to detect the total cholesterol (T-CHO) content, and were randomly divided into two groups according to the T-CHO content, and the vehicle PBS control group was given 7 cells. 6 lysogen group.
- the first dose was started on the first day.
- the plasminogen group was injected with human plasminogen 1 mg/0.1 ml/day/day into the tail vein, and the same volume of PBS was injected into the tail of the vehicle PBS control group.
- the high fat and high cholesterol feed was continued to be fed during the administration.
- Mice were sacrificed on day 31 and hearts were fixed in 4% paraformaldehyde for 24-48 hours.
- the fixed tissue was paraffin-embedded after dehydration by alcohol gradient and transparency of xylene.
- the thickness of the tissue section was 3 ⁇ m.
- the sections were dewaxed and rehydrated, washed once with water, stained with 0.1% Sirius red saturated picric acid for 30 minutes, rinsed with running water for 2 min, stained with hematoxylin for 1 minute, rinsed with water, differentiated with 1% hydrochloric acid, and returned to blue with ammonia. Rinse with running water, dry and seal with neutral gum, and observe under a 200x optical microscope.
- Sirius red staining can permanently stain collagen, which is a special staining method for collagen tissue in pathological sections to specifically display collagen tissue.
- the staining results showed that the deposition of collagen (arrow mark) in the plasminogen group (Fig. 21B) was significantly less than that in the vehicle PBS control group (Fig. 21A), indicating that plasminogen can reduce the heart of ApoE atherosclerotic model mice.
- the deposition of collagen in the tissue reduces cardiac fibrosis.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (69)
- 一种预防或治疗受试者心肌损伤的方法,包括给药受试者有效量的纤溶酶原,其中所述受试者有心肌损伤风险、怀疑有心肌损伤、或罹患心肌损伤。
- 权利要求1的方法,其中所述心肌损伤包括缺血、炎症、变态反应、自身免疫、血栓、微循环障碍、创伤、辐射损伤、糖代谢紊乱、脂肪代谢紊乱所致心肌损伤。
- 权利要求1或2的方法,其中所述心肌损伤为选自如下疾病导致的心肌损伤:心肌炎、心包炎、高血压、动脉粥样硬化、冠心病、心绞痛、心肌梗死、心律失常、心衰、休克、弥漫性血管内凝血、微循环障碍、糖尿病、高脂血症、动脉、静脉血栓、脂肪栓塞、缺血再灌注、系统性硬化症、系统性红斑狼疮、冠状动脉狭窄、风湿性心脏病、二尖瓣狭窄/关闭不全、主动脉瓣狭窄/关闭不全。
- 权利要求1或2的方法,其中所述心肌损伤为缺血性心脏疾病导致的心肌损伤。
- 权利要求4的方法,其中所述缺血性心脏疾病为动脉粥样硬化、冠心病、心绞痛、心肌梗死、心律失常、心衰、休克、弥漫性血管内凝血、微循环障碍、缺血再灌注、冠状动脉狭窄、二尖瓣狭窄/关闭不全、主动脉瓣狭窄/关闭不全。
- 权利要求1或2的方法,其中所述心肌损伤为动脉、静脉血栓或脂肪栓塞导致的心肌损伤。
- 权利要求6的方法,其中所述血栓或栓塞为动脉粥样硬化所致。
- 一种预防或治疗受试者心肌损伤的方法,包括给药受试者有效量的纤溶酶原保护心肌组织。
- 权利要求8的方法,其中所述纤溶酶原减轻心肌细胞损伤所致的心肌细胞凋亡。
- 权利要求8或9的方法,其中所述纤溶酶原促进损伤心肌的修复。
- 权利要求8-10任一项的方法,其中所述纤溶酶原减轻损伤心肌的纤维化。
- 权利要求8-11任一项的方法,其中所述纤溶酶原促进心肌功能恢复。
- 权利要求8-12任一项的方法,其中所述纤溶酶原减轻心肌受损后的扩张以及心脏代偿性肥大。
- 一种预防或治疗受试者脂质性心肌损伤的方法,包括给药受试者有效量的纤溶酶原保护心肌。
- 权利要求14的方法,其中所述纤溶酶原减轻脂质心脏组织沉积。
- 权利要求14或15的方法,其中所述纤溶酶原促进损伤心肌的修复。
- 权利要求14-16任一项的方法,其中所述纤溶酶原减轻损伤心肌组织的纤维化。
- 权利要求14-17任一项的方法,其中所述纤溶酶原减轻损伤心肌细胞的凋亡。
- 权利要求14-18任一项的方法,其中所述纤溶酶原促进心肌功能恢复。
- 权利要求14-19任一项的方法,其中所述纤溶酶原减轻心肌受损后的扩张以及心脏代偿性肥大。
- 权利要求14-20任一项的方法,其中所述纤溶酶原通过如下一项或多项减轻血脂:降低血清甘油三酯、低密度脂蛋白、极低密度脂蛋白、血清胆固醇、提高血清高密度脂蛋白。
- 一种预防或治疗受试者炎症性心肌损伤的方法,包括给药受试者有效量的纤溶酶原保护心肌。
- 权利要求22的方法,其中所述炎症为受试者自身免疫导致的炎症。
- 权利要求23的方法,其中所述炎症为系统性红斑狼疮、系统性硬化症,心肌炎、心包炎。
- 权利要求22-24任一项的方法,其中所述纤溶酶原促进损伤心肌的修复。
- 权利要求22-25任一项的方法,其中所述纤溶酶原减轻损伤心肌组织的纤维化。
- 权利要求22-26任一项的方法,其中所述纤溶酶原减轻损伤心肌细胞的凋亡。
- 权利要求22-27任一项的方法,其中所述纤溶酶原促进心肌功能恢复。
- 权利要求22-28任一项的方法,其中所述纤溶酶原减轻心肌受损后的扩张以及心脏代偿性肥大。
- 一种预防或治疗受试者冠状动脉硬化性心肌损伤的方法,包括给药受试者有效量的纤溶酶原保护心肌。
- 权利要求30的方法,其中所述心肌损伤为受试者冠心病所致。
- 权利要求31的方法,其中所述纤溶酶原促进损伤心肌的修复。
- 权利要求30-32任一项的方法,其中所述纤溶酶原减轻损伤心肌组织的纤维化。
- 权利要求30-33任一项的方法,其中所述纤溶酶原减轻损伤心肌细胞的凋亡。
- 权利要求30-34任一项的方法,其中所述纤溶酶原促进心肌功能恢复。
- 权利要求30-35任一项的方法,其中所述纤溶酶原减轻心肌受损后的扩张以及心脏代偿性肥大。
- 一种预防或治疗受试者糖尿病引发或并发的心肌损伤方法,包括给药受试者有效量的纤溶酶原保护心肌。
- 权利要求37的方法,其中所述纤溶酶原促进损伤心肌的修复。
- 权利要求37或38的方法,其中所述纤溶酶原减轻损伤心肌组织的纤维化。
- 权利要求37-39任一项的方法,其中所述纤溶酶原减轻损伤心肌细胞的凋亡。
- 权利要求37-40任一项的方法,其中所述纤溶酶原促进心肌功能恢复。
- 权利要求37-41任一项的方法,其中所述纤溶酶原减轻心肌受损后的扩张以及心脏代偿性肥大。
- 一种预防或治疗受试者脂质沉积导致的心肌损伤的方法,包括给药受试者有效量的纤溶酶原。
- 权利要求43的方法,其中所述脂质沉积是由于受试者脂肪代谢异常或糖代谢异常导致的高脂血症所致。
- 一种预防或治疗受试者高脂血症引发或伴随的肾组织损伤的方法,包括给药受试者有效量的纤溶酶原。
- 一种预防或治疗受试者缺血再灌注性心肌组织损伤的方法,包括给药受试者有效量的纤溶酶原。
- 根据权利要求1-46任一项的方法,其中所述纤溶酶原可与一种或多种其它药物或治疗手段联合施用。
- 权利要求47的方法,其中所述一种或多种其它药物包括高血压治疗药物、糖尿病治疗用药物、动脉粥样硬化治疗用药物、慢性肾小球肾炎治疗药物、慢性肾盂肾炎治疗药物、肾病综合征治疗用药物、肾功能不全治疗用药物、尿毒症治疗用药物、肾移植治疗用药物、脂肪肝治疗用药物、肝硬化治疗用药物、肥胖症治疗用药物。
- 根据权利要求48的方法,其中所述其它药物包括:降血脂药物、抗血小板药物、降血压药物、扩张血管药物、降血糖药物、抗凝血药物、溶血栓药物,保肝药物,抗心律失常药物,强心药物,利尿药物,抗感染药物、抗病毒药物、免疫调节药物、炎症调节类药物、抗肿瘤药物、激素类药物、甲状腺素。
- 权利要求49的方法,其中所述药物包括降血脂药物:他汀类;贝特类;烟酸;消胆胺;安妥明;不饱和脂肪酸如益寿宁、血脂平及心脉乐;藻酸双酯钠;抗血小板药物:阿司匹林;潘生丁;氯吡格雷;西洛他;扩张血管药物:肼苯哒嗪;硝酸甘油和消心痛;硝普钠;α硝受体阻断剂如哌唑嗪;α受体阻断剂如酚妥拉明;β拉受体兴奋剂如舒喘灵;卡托普利、依那普利;心痛定、硫氮卓酮;柳丁氨酸、长压定、前列腺素、心钠素;溶血栓药物:尿激酶和链激酶;组织型纤溶酶原激活剂;单链尿激酶型纤溶酶原激活剂;TNK-组织型纤溶酶原激活剂;抗凝血药物:肝素;依诺肝素;那曲肝素;比伐卢定。
- 权利要求1-50任一项的方法,其中所述纤溶酶原与序列2、6、8、10或12具有至少75%、80%、85%、90%、95%、96%、97%、98%或99%的序列同一性,并且仍然具有纤溶酶原活性。
- 权利要求1-51任一项的方法,所述纤溶酶原是在序列2、6、8、10或12的基础上,添加、删除和/或取代1-100、1-90、1-80、1-70、1-60、1-50、1-45、1-40、1-35、1-30、1-25、1-20、1-15、1-10、1-5、1-4、1-3、1-2、1个氨基酸,并且仍然具有纤溶酶原活性的蛋白质。
- 权利要求1-52任一项的方法,所述纤溶酶原是包含纤溶酶原活性片 段、并且仍然具有纤溶酶原活性的蛋白质。
- 权利要求1-53任一项的方法,所述纤溶酶原选自Glu-纤溶酶原、Lys-纤溶酶原、小纤溶酶原、微纤溶酶原、delta-纤溶酶原或它们的保留纤溶酶原活性的变体。
- 权利要求1-54任一项的方法,所述纤溶酶原为天然或合成的人纤溶酶原、或其仍然保留纤溶酶原活性的变体或片段。
- 权利要求1-54任一项的方法,所述纤溶酶原为来自灵长类动物或啮齿类动物的人纤溶酶原直向同系物或其仍然保留纤溶酶原活性的变体或片段。
- 权利要求1-56任一项的方法,所述纤溶酶原的氨基酸如序列2、6、8、10或12所示。
- 权利要求1-57任一项的方法,其中所述纤溶酶原是人天然纤溶酶原。
- 权利要求1-58任一项的方法,其中所述受试者是人。
- 权利要求1-59任一项的方法,其中所述受试者缺乏或缺失纤溶酶原。
- 权利要求60的方法,其中所述缺乏或缺失是先天的、继发的和/或局部的。
- 一种用于权利要求1-61任一项的方法的纤溶酶原。
- 一种药物组合物,其包含药学上可接受的载剂和用于权利要求1-61中任一项所述方法的纤溶酶原。
- 一种预防性或治疗性试剂盒,其包含:(i)用于权利要求1-61中任一项所述方法的纤溶酶原和(ii)用于递送所述纤溶酶原至所述受试者的构件(means)。
- 根据权利要求64所述的试剂盒,其中所述构件为注射器或小瓶。
- 权利要求64或65的试剂盒,其还包含标签或使用说明书,该标签或使用说明书指示将所述纤溶酶原投予所述受试者以实施权利要求1-46中任一项所述方法。
- 一种制品,其包含:含有标签的容器;和包含(i)用于权利要求1-61中任一项所述方法的纤溶酶原或包含纤溶酶原的药物组合物,其中所述标签指示将所述纤溶酶原或组合物投予所述受试者以实施权利要求1-61中任一项所述方法。
- 权利要求64-66中任一项的试剂盒或权利要求67的制品,还包含另外的一个或多个构件或容器,该构件或容器中含有其他药物。
- 权利要求68的试剂盒或制品,其中所述其他药物选自下组:降血脂药物、抗血小板药物、降血压药物、扩张血管药物、降血糖药物、抗凝血药物、溶血栓药物,保肝药物,抗心律失常药物,强心药物,利尿药物,抗感染药物、抗病毒药物、免疫调节药物、炎症调节类药物、抗肿瘤药物、激素类药物、甲状腺素。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/470,160 US11389515B2 (en) | 2016-12-15 | 2017-06-19 | Method for mitigating heart disease |
JP2019532072A JP7194440B2 (ja) | 2016-12-15 | 2017-06-19 | 心臓病変を改善するための方法 |
EP17880564.4A EP3556385A4 (en) | 2016-12-15 | 2017-06-19 | PROCESS FOR ALLEGING HEART DISEASE |
CN201780078125.8A CN110114081A (zh) | 2016-12-15 | 2017-06-19 | 一种改善心脏病变的方法 |
CA3047175A CA3047175A1 (en) | 2016-12-15 | 2017-06-19 | Method for mitigating heart disease |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2016110172 | 2016-12-15 | ||
CNPCT/CN2016/110174 | 2016-12-15 | ||
CNPCT/CN2016/110172 | 2016-12-15 | ||
CN2016110168 | 2016-12-15 | ||
CN2016110174 | 2016-12-15 | ||
CNPCT/CN2016/110168 | 2016-12-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018107707A1 true WO2018107707A1 (zh) | 2018-06-21 |
Family
ID=62558191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/089068 WO2018107707A1 (zh) | 2016-12-15 | 2017-06-19 | 一种改善心脏病变的方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US11389515B2 (zh) |
EP (1) | EP3556385A4 (zh) |
JP (1) | JP7194440B2 (zh) |
CN (1) | CN110114081A (zh) |
CA (1) | CA3047175A1 (zh) |
TW (1) | TWI677348B (zh) |
WO (1) | WO2018107707A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11207387B2 (en) | 2016-12-15 | 2021-12-28 | Talengen International Limited | Method and drug for preventing and treating obesity |
US11389515B2 (en) | 2016-12-15 | 2022-07-19 | Talengen International Limited | Method for mitigating heart disease |
US11478535B2 (en) | 2016-12-15 | 2022-10-25 | Talengen International Limited | Method for preventing and treating fatty liver |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110121358A (zh) | 2016-12-15 | 2019-08-13 | 泰伦基国际有限公司 | 一种预防和治疗肺纤维化的方法 |
WO2018233604A1 (zh) | 2017-06-19 | 2018-12-27 | 泰伦基国际有限公司 | 一种调控glp-1/glp-1r的方法和药物 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
EP0058481A1 (en) | 1981-02-16 | 1982-08-25 | Zeneca Limited | Continuous release pharmaceutical compositions |
WO1997004801A1 (en) | 1995-07-27 | 1997-02-13 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
CN1662548A (zh) * | 2002-04-23 | 2005-08-31 | 纽约市哥伦比亚大学信托人 | 通过诱导新血管形成使内生性心肌组织再生 |
CN1668645A (zh) * | 2002-05-17 | 2005-09-14 | 埃斯佩里安医疗公司 | 治疗缺血再灌注的方法和组合物 |
CN101132788A (zh) * | 2005-03-01 | 2008-02-27 | 瑟维尔实验室 | 用于治疗和预防血栓形成疾病的香叶木素衍生物 |
CN102154253A (zh) | 2011-01-06 | 2011-08-17 | 郑州大学 | 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途 |
US20120058537A1 (en) * | 2011-07-27 | 2012-03-08 | Fereidoun Mahboudi | Chimeric truncated and mutant variant of tissue plasminogen activator (t-pa) resistant to plasminogen activator inhibitor-1 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4245051A (en) | 1978-03-30 | 1981-01-13 | Rockefeller University | Human serum plasminogen activator |
JPS62153224A (ja) | 1985-12-27 | 1987-07-08 | Green Cross Corp:The | プラスミノゲン製剤 |
GB8721951D0 (en) * | 1987-09-18 | 1987-10-28 | Thrombosis Research Trust | Organic compounds |
JP2764264B2 (ja) | 1987-10-01 | 1998-06-11 | 株式会社ミドリ十字 | 線溶活性増強剤 |
AT402367B (de) | 1990-10-11 | 1997-04-25 | Immuno Ag | Pharmazeutische zubereitung auf basis von lys-plasminogen |
WO1994001128A1 (en) | 1992-07-01 | 1994-01-20 | Beth Israel Hospital Boston | Enhancement of thrombolytic therapy with deglycosylated plasminogen |
US5520912A (en) * | 1993-07-02 | 1996-05-28 | Immuno Aktiengesellschaft | Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen |
DK125693D0 (zh) | 1993-11-05 | 1993-11-05 | Novo Nordisk As | |
DE4411143C2 (de) | 1994-03-30 | 1996-08-01 | Immuno Ag | Thrombosemittel |
JP2002510209A (ja) | 1997-06-26 | 2002-04-02 | カロリンスカ イノベイションズ アクチボラゲット | インビボで血管形成を調節することができるプラスミノーゲンのクリングルドメイン1−5 |
US7317003B2 (en) | 1998-09-04 | 2008-01-08 | National University Of Singapore | Small peptides having anti-angiogenic and endothelial cell inhibition activity |
WO2000049871A1 (en) | 1999-02-24 | 2000-08-31 | Henry Ford Health System | An anti-angiogenic kringle protein and its mutants |
US6899877B2 (en) | 1999-03-09 | 2005-05-31 | Minu, L.L.C. | Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina |
US7544500B2 (en) | 1999-11-13 | 2009-06-09 | Talecris Biotherapeutics, Inc. | Process for the production of a reversibly inactive acidified plasmin composition |
US6964764B2 (en) | 1999-11-13 | 2005-11-15 | Talecris Biotherapeutics, Inc. | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
US20020159992A1 (en) | 2000-09-29 | 2002-10-31 | Jack Henkin | Antiangiogenic polypeptides and methods for inhibiting angiogenesis |
WO2002040510A2 (en) | 2000-11-02 | 2002-05-23 | Bristol-Myers Squibb Company | Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors |
CA2455336A1 (en) | 2001-08-10 | 2003-02-20 | Novartis Ag | Peptides that bind to atherosclerotic lesions |
US7067492B2 (en) * | 2001-09-06 | 2006-06-27 | Omnio Ab | Method of promoting healing of a tympanic membrane perforation |
US7202066B2 (en) | 2002-01-29 | 2007-04-10 | Carrington Laboratories, Inc. | Combination of a growth factor and a protease enzyme |
AU2003210137A1 (en) * | 2002-02-06 | 2003-09-02 | N-Zyme Biotec Gmbh | Method for producing recombinant proteins in micro-organisms |
US20050124036A1 (en) | 2002-02-06 | 2005-06-09 | Rudy Susilo | Method for producing recombinant proteins in micro-organisms |
CN1451746A (zh) | 2003-03-20 | 2003-10-29 | 广州市启源生物科技有限公司 | 人纤溶酶原Kringle 5缺失突变重组多肽 |
WO2005028690A1 (en) | 2003-09-24 | 2005-03-31 | Alstom Technology Ltd | Braze alloy and the use of said braze alloy |
US8357147B2 (en) | 2005-08-17 | 2013-01-22 | Spinal Restoration, Inc. | Method for repairing intervertebral discs |
AU2006227133A1 (en) * | 2005-03-22 | 2006-09-28 | Georgetown University | Delivery systems and methods for diagnosing and treating cardiovascular diseases |
US20060257391A1 (en) | 2005-05-11 | 2006-11-16 | Bausch & Lomb Incorporated | Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions |
US20100028321A1 (en) * | 2006-08-28 | 2010-02-04 | Omnio Healer Ab | Drug target for preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health |
WO2008026999A2 (en) | 2006-08-28 | 2008-03-06 | Omnio Healer Ab | Candidates against infection |
CN101219219B (zh) | 2007-01-10 | 2013-02-13 | 北京普罗吉生物科技发展有限公司 | 包含血管抑素或其片段的复合物、其制备方法及应用 |
CN101015686B (zh) | 2007-02-06 | 2010-05-19 | 中国人民解放军军事医学科学院基础医学研究所 | 一种溶栓药物增效剂及其制备方法 |
US20080200387A1 (en) | 2007-02-15 | 2008-08-21 | Hua-Lin Wu | Anti-angiogenic protein, composition and use thereof |
AR067446A1 (es) | 2007-07-11 | 2009-10-14 | Otsuka Pharma Co Ltd | Un medicamento para tratar higado graso que comprende cilostazol |
US8101394B2 (en) | 2007-11-29 | 2012-01-24 | Grifols Therapeutics Inc. | Recombinantly modified plasmin |
JP2011509093A (ja) | 2008-01-09 | 2011-03-24 | イントレキソン コーポレーション | Pai−1機能の治療的阻害因子およびその使用法 |
US20090208448A1 (en) | 2008-02-15 | 2009-08-20 | Solomon Keith R | Inhibition of angiogenesis |
EP2607348B8 (en) | 2009-03-31 | 2021-04-21 | Renascience Inc. | Plasminogen Activator Inhibitor-1 Inhibitor |
EP2424561A2 (en) | 2009-04-30 | 2012-03-07 | Catherine Blondel | Methods for treating ocular conditions |
NZ597452A (en) | 2009-07-10 | 2013-10-25 | Thrombogenics Nv | Variants of plasminogen and plasmin |
CN101628113B (zh) | 2009-08-18 | 2012-01-04 | 南京农业大学 | 蚯蚓纤溶酶抗肝纤维化的应用 |
CN102121023B (zh) | 2010-12-22 | 2012-07-04 | 中山大学 | 突变型人纤溶酶原kringle5及其制备方法及应用 |
EP2661493B1 (en) | 2011-01-05 | 2016-03-30 | ThromboGenics N.V. | Plasminogen and plasmin variants |
CN102199587B (zh) | 2011-03-24 | 2013-06-19 | 广东药学院 | 人纤溶酶原功能性突变体及其制备方法和应用 |
US9644196B2 (en) | 2011-08-12 | 2017-05-09 | Thrombogenics Nv | Plasminogen and plasmin variants |
CN103656630B (zh) | 2012-09-11 | 2015-07-08 | 江苏仁寿药业有限公司 | 一种提纯动物药材中纤溶酶并制备成中药组合物的方法 |
CA2888996A1 (en) | 2012-10-31 | 2014-05-08 | The Regents Of The University Of Michigan | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof |
WO2014160275A2 (en) | 2013-03-14 | 2014-10-02 | Battell Memorial Institute | Biomarkers for liver fibrosis |
CN104274449A (zh) | 2013-07-11 | 2015-01-14 | 无锡信达医疗器械有限公司 | 治疗肥胖症的药物组合物 |
TWI801331B (zh) | 2015-11-03 | 2023-05-11 | 美商波麥堤克生物治療股份有限公司 | 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法 |
WO2017101871A1 (zh) * | 2015-12-18 | 2017-06-22 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗心血管病的新方法 |
CN109069567A (zh) | 2015-12-18 | 2018-12-21 | 泰伦基国际有限公司 | 一种预防或治疗糖尿病性神经损伤及其相关病症的方法 |
CA3008185C (en) | 2015-12-18 | 2024-01-16 | Talengen International Limited | Method for prevention or treatment of acute and chronic thrombosis |
CA3008475C (en) | 2015-12-18 | 2024-06-04 | Talengen International Limited | Method for preventing and treating hepatic tissue injury and related disorders thereof |
EP3395354B1 (en) | 2015-12-18 | 2024-05-22 | Talengen International Limited | Plasminogen for use in treating diabetic nephropathy |
EP3251689A1 (en) | 2016-06-02 | 2017-12-06 | IMV Technologies | Use of la1-like peptide isolated from maurus palmatus venom as an activator of sperm motility in mammals |
CA3047181A1 (en) | 2016-12-15 | 2018-06-21 | Talengen International Limited | Method and drug for preventing and treating obesity |
JP7158740B2 (ja) | 2016-12-15 | 2022-10-24 | タレンゲン インターナショナル リミテッド | 冠状動脈アテローム性硬化症およびその合併症を治療するための方法 |
JP7194440B2 (ja) | 2016-12-15 | 2022-12-22 | タレンゲン インターナショナル リミテッド | 心臓病変を改善するための方法 |
TW201904990A (zh) | 2017-06-23 | 2019-02-01 | 美商波麥堤克生物治療股份有限公司 | 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療 |
JP6780807B2 (ja) | 2018-07-05 | 2020-11-04 | 三菱電機株式会社 | エレベーターの群管理装置およびエレベーターシステム |
-
2017
- 2017-06-19 JP JP2019532072A patent/JP7194440B2/ja active Active
- 2017-06-19 EP EP17880564.4A patent/EP3556385A4/en active Pending
- 2017-06-19 TW TW106120460A patent/TWI677348B/zh active
- 2017-06-19 WO PCT/CN2017/089068 patent/WO2018107707A1/zh unknown
- 2017-06-19 CN CN201780078125.8A patent/CN110114081A/zh active Pending
- 2017-06-19 US US16/470,160 patent/US11389515B2/en active Active
- 2017-06-19 CA CA3047175A patent/CA3047175A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
EP0058481A1 (en) | 1981-02-16 | 1982-08-25 | Zeneca Limited | Continuous release pharmaceutical compositions |
WO1997004801A1 (en) | 1995-07-27 | 1997-02-13 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
CN1662548A (zh) * | 2002-04-23 | 2005-08-31 | 纽约市哥伦比亚大学信托人 | 通过诱导新血管形成使内生性心肌组织再生 |
CN1668645A (zh) * | 2002-05-17 | 2005-09-14 | 埃斯佩里安医疗公司 | 治疗缺血再灌注的方法和组合物 |
CN101132788A (zh) * | 2005-03-01 | 2008-02-27 | 瑟维尔实验室 | 用于治疗和预防血栓形成疾病的香叶木素衍生物 |
CN102154253A (zh) | 2011-01-06 | 2011-08-17 | 郑州大学 | 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途 |
US20120058537A1 (en) * | 2011-07-27 | 2012-03-08 | Fereidoun Mahboudi | Chimeric truncated and mutant variant of tissue plasminogen activator (t-pa) resistant to plasminogen activator inhibitor-1 |
Non-Patent Citations (33)
Title |
---|
"Remington's Pharmaceutical Sciences", 1980 |
ASHISH ANEJAW.H. WILSON TANGSAMEER BANSILAL ET AL.: "Diabetic Cardiomyopathy: Insights into Pathogenesis, Diagnostic Challenges, and Therapeutic Options", AM J MED., vol. 121, no. 9, September 2008 (2008-09-01), pages 748 - 57, XP024098498, DOI: doi:10.1016/j.amjmed.2008.03.046 |
BARANYSOLID-PHASE PEPTIDE SYNTHESIS, THE PEPTIDES: ANALYSIS, SYNTHESIS, BIOLOGY. VOL. 2: SPECIAL METHODS IN PEPTIDE SYNTHESIS, vol. 2, pages 3 - 284 |
CAMARERO JA ET AL., PROTEIN PEPT LETT., vol. 12, 2005, pages 723 - 8 |
CHEN ET AL: "KATP channels outside pancreas and glucose metabolism", INTERNATIONAL JOURNAL OF ENDOCRINOLOGY ND METABOLISM, vol. 29, no. 5, 30 September 2009 (2009-09-30), pages 332 - 334, XP009515350, DOI: 10.3760/cma.j.issn.1673-4157.2007.05.013 * |
CO ET AL., J. IMMUNOL., vol. 148, 1992, pages 1149 |
DATABASE Protein 15 March 2015 (2015-03-15), BUTERA, D.: "plasminogen isoform 1 precursor", XP055493720, retrieved from NCBI Database accession no. NP_000292.1 * |
DIMITRIOS DAVALOSKATERINA AKASSOGLOU: "Fibrinogen as a key regulator of inflammation in disease", SEMINARS IN IMMUNOPATHOLOGY, vol. 34, no. l, 2012, pages 43 - 62 |
DOMINIKA NACKIEWICZPAROMITA DEYBARBARA SZCZERBA ET AL.: "Inhibitor of differentiation 3, a transcription factor regulates hyperlipidemia associated kidney disease", NEPHRON EXP NEPHROL., vol. 126, no. 3, 2014, pages 141 - 147 |
GANESAN A., MINI REV. MED CHEM., vol. 6, 2006, pages 3 - 10 |
HAO WFRIEDMAN A: "The LDL-HDL Profile Determines the Risk of Atherosclerosis: A Mathematical Model", PLOS ONE, vol. 9, no. 3, 2014, pages e90497 |
HARDY, D.S.D.M. HOELSCHERC. ARAGAKI ET AL.: "Association of glycemic index and glycemic load with risk of incident coronary heart disease among Whites and African Americans with and without type 2 diabetes: the atherosclerosis risk in communities study", ANN. EPIDEMIOL., vol. 20, 2010, pages 610 - 616, XP027120889 |
KIM SJGERSHOV DMA XBROT NELKON KB, I-PLA2 ACTIVATION DURING APOPTOSIS PROMOTES THE EXPOSURE OF MEMBRANE LYSOPHOSPHATIDYLCHOLINE LEADING TO BINDING BY NATURAL IMMUNOGLOBULIN M ANTIBODIES AND COMPLEMENT, 2002 |
LANGER ET AL., J. BIOMED. MATER. RES., vol. 15, 1981, pages 167 - 277 |
LANGER, CHEM. TECH., vol. 12, 1982, pages 98 - 105 |
MERRIFIELD ET AL., J. AM. CHEM. SOC., vol. 85, 1963, pages 2149 - 2156 |
MING GULYU ZHANG.SHENGJIE FAN ET AL.: "Extracts of RhizomaPolygonatiOdorati Prevent High-Fat Diet-Induced Metabolic Disorders in C57BL/6 Mice", PLOS ONE, vol. 8, no. 11, pages e81724 |
PENG ET AL: "Protective effect of Recombinant tissue plasminogen activator on acute myocardial infarction in Senile Rats", CHINESE JOURNAL OF GERONTOLOGY, vol. 25, no. 12, 31 December 2005 (2005-12-31), pages 1517 - 1518, XP009515354, ISSN: 1005-9202 * |
QUEEN ET AL., IMMUNOL. REV., vol. 89, 1986, pages 49 |
R. LANGHORNJ.L. WILLESEN: "Cardiac Troponins in Dogs and Cats", J VET INTERN MED, vol. 30, 2016, pages 36 - 50 |
SAMUELCSLHEWITSONTDZHANGY ET AL.: "Relaxin ameliorates fibrosis in experimental diabetc cardiomyopathy", ENDOCRINOLOGY, vol. 149, no. 7, July 2008 (2008-07-01), pages 3286 - 93 |
See also references of EP3556385A4 |
SIDMAN ET AL., BIOPOLYMERS, vol. 22, 1983, pages 547 |
SIOBHAN M. CRAIGEPHD, SHASHI KANT ET AL.: "Endothelial NADPH oxidase 4 protects ApoE-/- mice from atherosclerotic lesions", FREE RADICBIOL MED., vol. 89, December 2015 (2015-12-01), pages 1 - 7, XP029334788, DOI: doi:10.1016/j.freeradbiomed.2015.07.004 |
STEWART ET AL.: "Solid Phase Peptide Synthesis", 1984, PIERCE CHEM. CO. |
SUN MI HWANGJIN SOOK KIMYUN JUNG LEE ET AL.: "Anti-Diabetic Atherosclerosis Effect of Prunella vulgaris in db/db Mice with Type 2 Diabetes", THE AMERICAN JOURNAL OF CHINESE MEDICINE, vol. 40, no. 5, pages 937 - 951 |
WANG ET AL: "Protective effect of rt-PA on experimental myocardial ischemia in rats", JOURNAL OF CARDIOVASCULAR AND PULMONARY DISEASES, vol. 23, no. 4, 30 November 2004 (2004-11-30), pages 238 - 239, XP009515353, ISSN: 1007-5062 * |
WANG GANG: "Effects of Actilyse on hemorheology in rats with acute ischemic myocardial injure", CHINESE JOURNAL OF CARDIOVASCULAR REHABILITATION MEDICINE, vol. 16, no. 4, 31 August 2007 (2007-08-31), pages 369 - 371, XP009515349, ISSN: 1008-0074 * |
WINNACKER: "From Genes to Clones", 1987, VCH PUBLISHERS |
YOSUKE KANNOEN SHUHIROYUKI KANOH ET AL.: "The Antifibrotic Effect of a2AP Neutralization in Systemic Sclerosis Dermal Fibroblasts and Mouse Models of Systemic Sclerosis", J INVEST DERMATOL., vol. 136, no. 4, April 2016 (2016-04-01), pages 762 - 9 |
YUTAKA NAKASHIMAANDREW S. PLUMPELAINE W ET AL., RAINES ET AL. ARTERIOSCLER THROMB., vol. 14, no. l, January 1994 (1994-01-01), pages 133 - 40 |
YVONNE NITSCHKEGABRIELE WEISSEN-PLENZROBERT TERKELTAUB ET AL.: "Nppl promotes atherosclerosis in ApoE knockout mice", J. CELL. MOL. MED., vol. 15, no. 11, 2011, pages 2273 - 2283, XP055400747, DOI: doi:10.1111/j.1582-4934.2011.01327.x |
ZHANG MTAKAHASHI KALICOT EMVORUP-JENSEN TKESSLER B ET AL.: "Activation of the lectin pathway by natural IgM in a model of ischemia/reperfusion injury", J IMMUNOL, vol. 177, 2006, pages 4727 - 4734 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11207387B2 (en) | 2016-12-15 | 2021-12-28 | Talengen International Limited | Method and drug for preventing and treating obesity |
US11389515B2 (en) | 2016-12-15 | 2022-07-19 | Talengen International Limited | Method for mitigating heart disease |
US11478535B2 (en) | 2016-12-15 | 2022-10-25 | Talengen International Limited | Method for preventing and treating fatty liver |
US11547746B2 (en) | 2016-12-15 | 2023-01-10 | Talengen International Limited | Method for treating coronary atherosclerosis and complications thereof |
Also Published As
Publication number | Publication date |
---|---|
US20190343931A1 (en) | 2019-11-14 |
JP2020502155A (ja) | 2020-01-23 |
EP3556385A4 (en) | 2020-12-30 |
TW201822798A (zh) | 2018-07-01 |
JP7194440B2 (ja) | 2022-12-22 |
TWI677348B (zh) | 2019-11-21 |
EP3556385A1 (en) | 2019-10-23 |
CN110114081A (zh) | 2019-08-09 |
US11389515B2 (en) | 2022-07-19 |
CA3047175A1 (en) | 2018-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI680764B (zh) | 一種預防動脈粥樣硬化及其併發症的方法 | |
WO2018107707A1 (zh) | 一种改善心脏病变的方法 | |
WO2018107698A1 (zh) | 一种预防和治疗组织器官纤维化的方法 | |
WO2018108161A1 (zh) | 一种预防和治疗肥胖症的方法和药物 | |
TWI746581B (zh) | 纖溶酶原在製備預防和治療脂質腎損傷之藥劑上的用途 | |
WO2018107695A1 (zh) | 一种预防和治疗肾纤维化的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17880564 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3047175 Country of ref document: CA Ref document number: 2019532072 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017880564 Country of ref document: EP Effective date: 20190715 |